var title_f21_57_22416="Esophageal foreign body CPC";
var content_f21_57_22416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Esophageal foreign body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Postero-anterior radiology image showing the crucifix portion of the necklace lodged in the distal esophagus with extension of the chain into the stomach. There are multiple healed left rib fractures and metallic foreign body from previous gunshot wound in the left chest. (B) Lateral view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher W. Duncan MD, MPP and Lehel, Somogyi MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22416=[""].join("\n");
var outline_f21_57_22416=null;
var title_f21_57_22417="Infiltrative dermopathy";
var content_f21_57_22417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infiltrative dermopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Infiltrative dermopathy in a patient with Graves' disease showing bilateral involvement with an orange-peel appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Terry F Davies, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22417=[""].join("\n");
var outline_f21_57_22417=null;
var title_f21_57_22418="Cobblestone in Crohns SBFT";
var content_f21_57_22418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cobblestone appearance in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel follow through study demonstrates diffuse thickening of the small bowel mucosa in a patient with Crohn's disease. The cobblestone appearance is produced by barium being dispersed between the edematous inflamed mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22418=[""].join("\n");
var outline_f21_57_22418=null;
var title_f21_57_22419="Insulinoma insulin stain";
var content_f21_57_22419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Insulinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 178px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Insulin staining of normal pancreas (left panel) and an insulin-secreting pancreatic tumor (right panel) (x 40).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of F John Service, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22419=[""].join("\n");
var outline_f21_57_22419=null;
var title_f21_57_22420="Peliosis hepatis low power";
var content_f21_57_22420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peliosis hepatis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This low power (4x) view of a liver biopsy with H&amp;E stain shows patches of sinusoidal dilatation and small cyst formation between areas of grossly normal liver parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tracy Challies, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22420=[""].join("\n");
var outline_f21_57_22420=null;
var title_f21_57_22421="Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction";
var content_f21_57_22421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22421/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22421/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22421/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22421/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22421/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22421/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/57/22421/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable angina and non-ST elevation (non-Q wave) myocardial infarction (NSTEMI) are part of the continuum of acute coronary syndrome (ACS) that also includes ST elevation MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two observations constitute the rationale for consideration of the use of fibrinolytic agents in the treatment of unstable angina or acute NSTEMI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The important role of intraarterial thrombus formation in this disorder",
"     </li>",
"     <li>",
"      The efficacy of fibrinolysis in the management of acute ST elevation (Q wave) MI (STEMI).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In STEMI, fibrinolytic agents offer a trade-off between reduced mortality and increased incidence of intracerebral bleeding. In this setting, the net benefit is expressed as a difference between these two events. The choice of dose and the means of administration (eg, rapid bolus loading and concomitant intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) is influenced by the need to achieve rapid reperfusion to preserve as much myocardium as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of important differences in unstable",
"    <span class=\"nowrap\">",
"     angina/NSTEMI:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In-hospital mortality is much less with unstable angina than with STEMI, and the most serious complication is progression to MI [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/1\">",
"       1",
"      </a>",
"      ]. In-hospital mortality also is lower with NSTEMI than STEMI, although the long-term prognosis is similar or worse (",
"      <a class=\"graphic graphic_figure graphicRef61809 \" href=\"UTD.htm?32/35/33341\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology of coronary heart disease\", section on 'STEMI versus NSTEMI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although unstable angina syndromes imply the presence of myocardium at risk, there is no time-dependent loss of myocardium.",
"     </li>",
"     <li>",
"      There is already a well defined set of therapeutic interventions (intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ) that dramatically reduce ischemic complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, the use of fibrinolytic agents in unstable",
"    <span class=\"nowrap\">",
"     angina/NSTEMI",
"    </span>",
"    must be essentially complication-free to be clinically acceptable. This necessarily reduces the available dose of fibrinolytic drugs, raising the question of whether lower doses will be effective in lysing intraarterial thrombi.",
"   </p>",
"   <p>",
"    A number of major trials have attempted to explore these issues with largely negative results. Coronary arteriography, performed in the acute period following a non-ST elevation acute coronary syndrome, demonstrates that the culprit artery is not occluded in 60 to 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The nonoccluding thrombi that are present are primarily grayish-white (ie, platelet-rich), and therefore less likely to respond to fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/7\">",
"     7",
"    </a>",
"    ], in contrast to being almost always reddish (ie, fibrin-rich) in patients with ST elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, microvascular perfusion is often reduced in unstable",
"    <span class=\"nowrap\">",
"     angina/NSTEMI;",
"    </span>",
"    as a result, the ongoing mechanism of ischemia is more likely embolization than epicardial vessel occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRAVENOUS FIBRINOLYSIS TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of small trials and the large TIMI III trial (Thrombolysis in Myocardial Infarction) examined the use of intravenous fibrinolysis in patients with unstable angina and NSTEMI.",
"   </p>",
"   <p>",
"    The initial trials of carefully selected patients with severe unstable angina and documented significant coronary disease failed, with one exception, to demonstrate any angiographic benefit of fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. Some of the trials suggested clinical benefit even in the absence of angiographic improvement but this was not a consistent finding.",
"   </p>",
"   <p>",
"    In the trial with positive angiographic results, 24 patients with rest angina and ischemic ST segment depressions of &gt;1 mm were randomly assigned to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator, 1.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 12 hours) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/9\">",
"     9",
"    </a>",
"    ]. At a follow-up angiography approximately seven days later, 8 of 11 controls but none of the alteplase-treated patients had subocclusive thrombi. Bleeding complications necessitating cessation of infusion occurred in 3 of 12 patients in the alteplase group. The dose of alteplase employed in this study was well in excess of other trials and considerably higher than is customarily used in acute MI protocols.",
"   </p>",
"   <p>",
"    A second trial evaluated the use of different",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    doses. Sixty-seven patients with rest angina and angiographic evidence of coronary stenosis were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    plus reduced dose alteplase (0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over one hour), full dose alteplase (0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over one hour, total dose of 100 mg over six hours), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/12\">",
"     12",
"    </a>",
"    ]. Repeat angiography at 24 to 48 hours failed to demonstrate any difference between the three groups although there was considerable individual variation in the response to therapy.",
"   </p>",
"   <p>",
"    The efficacy of intravenous urokinase (3 million units over 90 minutes) was explored in a trial of 149 patients with rest angina who were randomly assigned to urokinase and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , urokinase and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or heparin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/14\">",
"     14",
"    </a>",
"    ]. At 96 hours, there was no difference in clinical outcomes (new myocardial infarction, intractable angina, or death) in the treatment groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     TIMI IIIA and IIIB trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;TIMI III is the most comprehensive trial to assess the role of fibrinolysis in non-ST elevation acute coronary syndromes. This trial evaluated patients with unstable angina or NSTEMI and objective evidence of coronary disease. It incorporated both an angiographic arm designed to assess angiographic benefit (TIMI IIIA) and a clinical outcomes arm (TIMI IIIB). Patients were treated with conventional therapy and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) and then randomly assigned to placebo or a 90 minute front-loaded infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (0.8",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum dose of 80 mg).",
"   </p>",
"   <p>",
"    In the angiographic arm, 306 patients had a baseline coronary angiogram and a follow-up angiogram an average of 24 hours later [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/4\">",
"     4",
"    </a>",
"    ]. Intracoronary thrombi were seen at baseline in 35 percent of the patients. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Substantial improvement in thrombus appearance was significantly more frequent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (36 versus 15 percent) and in patients with an evolving NSTEMI.",
"     </li>",
"     <li>",
"      The overall benefit (&gt;10 percent improvement in diameter stenosis or two TIMI grade improvement in flow) was not significantly different between the two groups. Substantial improvement (&gt;20 percent improvement in diameter stenosis) was infrequent but significantly more common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (15 versus 5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, this detailed angiographic study showed only a modest benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    administration.",
"   </p>",
"   <p>",
"    The clinical outcomes arm (TIMI IIIB) involved 1473 patients with unstable angina or NSTEMI and evaluated both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    therapy and early invasive versus conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Alteplase administration was",
"    <strong>",
"     not",
"    </strong>",
"    associated with any improvement in primary end points (death, MI, or failure of initial therapy) at six weeks or one year (",
"    <a class=\"graphic graphic_figure graphicRef62600 \" href=\"UTD.htm?6/61/7133\">",
"     figure 2",
"    </a>",
"    ). To the contrary, fatal and nonfatal myocardial infarctions occurred significantly more frequently with alteplase (7.4 versus 4.9 percent). There was also a trend toward a higher incidence of severe hemorrhagic events in the alteplase group, with intracerebral hemorrhage occurring in four patients versus no controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=see_link\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     LATE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LATE (Late Assessment of Thrombolytic Efficacy) trial evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (versus placebo) administered 6 to 24 hours after the onset of chest pain in patients with symptoms and ECG evidence of an STEMI or NSTEMI, or elevated serum cardiac enzyme levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Among a subgroup of approximately 1300 patients with NSTEMI, it was suggested that alteplase was associated with a reduction in reinfarction and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, important limitations to these findings. The results in the patients with STEMI, representing a retrospective subgroup analysis, are contradictory to other studies such as TIMI IIIB, and used a retrospective definition of NSTEMI. We therefore feel that these observations should not be taken as evidence of benefit from fibrinolysis in NSTEMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of a number of smaller trials and the comprehensive TIMI III trial strongly argue",
"    <strong>",
"     against",
"    </strong>",
"    the use of intravenous thrombolytic therapy in unstable angina or NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/19\">",
"     19",
"    </a>",
"    ]. The 2007 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines on the management of non-ST elevation acute coronary syndromes recommend against the use of fibrinolytic therapy in patients with non-ST elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22421/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/1\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/2\">",
"      Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001; 37:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/3\">",
"      Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/4\">",
"      Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/5\">",
"      Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002; 39:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/6\">",
"      Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/7\">",
"      Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/8\">",
"      Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/9\">",
"      Gold HK, Johns JA, Leinbach RC, et al. A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris. Circulation 1987; 75:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/10\">",
"      Nicklas JM, Topol EJ, Kander N, et al. Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina. J Am Coll Cardiol 1989; 13:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/11\">",
"      Ardissino D, Barberis P, De Servi S, et al. Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris. Am J Cardiol 1990; 66:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/12\">",
"      Williams DO, Topol EJ, Califf RM, et al. Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial. Circulation 1990; 82:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/13\">",
"      Freeman MR, Langer A, Wilson RF, et al. Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo. Circulation 1992; 85:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/14\">",
"      Schreiber TL, Rizik D, White C, et al. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation 1992; 86:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/15\">",
"      Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/16\">",
"      Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/17\">",
"      Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/18\">",
"      Langer A, Goodman SG, Topol EJ, et al. Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators). J Am Coll Cardiol 1996; 27:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22421/abstract/19\">",
"      Anderson HV. Intravenous thrombolysis in refractory unstable angina pectoris. Lancet 1995; 346:1113.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 56 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-222.169.60.2-DB8828736C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22421=[""].join("\n");
var outline_f21_57_22421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRAVENOUS FIBRINOLYSIS TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMI IIIA and IIIB trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LATE trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/56\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/56|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/35/33341\" title=\"figure 1\">",
"      Survival in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/61/7133\" title=\"figure 2\">",
"      TPA does not reduce cardiac events in unstable angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=related_link\">",
"      Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_57_22422="Thyroid extract (desiccated thyroid): Pediatric drug information";
var content_f21_57_22422=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thyroid extract (desiccated thyroid): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9846?source=see_link\">",
"    see \"Thyroid extract (desiccated thyroid): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/28/32197?source=see_link\">",
"    see \"Thyroid extract (desiccated thyroid): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Armour&reg; Thyroid;",
"     </li>",
"     <li>",
"      Nature-Throid&trade;;",
"     </li>",
"     <li>",
"      Westhroid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F14851204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Thyroid Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F14851338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses presented as mg/kg/dose or mg/dose; closely review dosing units; adjust dose based upon clinical response and laboratory parameters",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Congenital hypothyroidism:",
"     </b>",
"     Oral: 4.8-6 mg/kg/dose or 15-30 mg/dose once daily.",
"     <b>",
"      Note:",
"     </b>",
"     AAP recommends levothyroxine as the preferred treatment for hypothyroidism in neonates (AAP, 2006). Neonates should have therapy initiated at full doses.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F14851211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9846?source=see_link\">",
"      see \"Thyroid extract (desiccated thyroid): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Doses presented as mg/kg/dose or mg/dose; closely review dosing units; adjust dose based upon clinical response and laboratory parameters.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Congenital Hypothyroidism: Note:",
"     </b>",
"     Infants should have therapy initiated at full doses; Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 1--6 months: 4.8-6 mg/kg/dose or 15-30 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants &gt;6-12 months: 3.6-4.8 mg/kg/dose or 30-45 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 1-5 years: 3-3.6 mg/kg/dose or 45-60 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-12 years: 2.4-3 mg/kg/dose or 60-90 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: Typical doses &gt;1.2-1.8 mg/kg/dose or 90 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     The American Association of Clinical Endocrinologists does not recommend the use of desiccated thyroid for thyroid replacement therapy for hypothyroidism (Baskin, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Oral: Initial: 15-30 mg; increase with 15 mg increments every 2-3 weeks; use 15 mg in patients with cardiovascular disease or long-standing myxedema. Maintenance dose: Usually 60-120 mg/day; monitor TSH and clinical symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 30 mg [DSC], 60 mg [DSC], 120 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Armour&reg; Thyroid: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Armour&reg; Thyroid: 180 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Armour&reg; Thyroid: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Armour&reg; Thyroid: 300 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nature-Throid&trade;: 16.25 mg, 32.5 mg, 65 mg, 130 mg, 195 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Westhroid&trade;: 32.5 mg, 65 mg, 130 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14851212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach in the morning before breakfast.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F14851280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14851205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement or supplemental therapy in hypothyroidism of any etiology (FDA approved in all ages); pituitary TSH suppressant for the treatment or prevention of various types of euthyroid goiter, thyroid nodules, thyroiditis, multinodular goiter, and thyroid cancer (FDA approved in adults);",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for treatment of transient hypothyroidism associated with subacute thyroiditis.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9954591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F227368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions often indicative of excess thyroid replacement and/or hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Alopecia, cardiac arrhythmia, chest pain, dyspnea, excessive bone loss with overtreatment (excess thyroid replacement), hand tremor, myalgia, palpitation, tachycardia, tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14851206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pork or any component; untreated thyrotoxicosis; uncorrected adrenal insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14851279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Use with caution and reduce dosage in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease. Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated. May cause transient alopecia in children during the first few months of therapy. In neonates and infants, cardiac overload, arrhythmias, and aspiration from avid suckling may occur during initiation of therapy (eg, first 2 weeks); monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14851207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Not for use in the treatment of obesity or for weight loss",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; in euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction; larger doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs (sympathomimetic amines). Overtreatment may result in craniosynostosis in infants and premature closure of epiphyses in children; monitor use closely. Should not be used for treatment of infertility without unrelated hypothyroidism.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F14851208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Management: Take in the morning before breakfast on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12966353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Liothyronine has not been found to increase the risk of teratogenic or adverse effects following maternal use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes. To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14851213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     , TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; growth, bone development (children); TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T",
"     <sub>",
"      4",
"     </sub>",
"     remains low and TSH is within normal limits, an evaluation of &ldquo;free&rdquo; (unbound) T",
"     <sub>",
"      4",
"     </sub>",
"     is needed to evaluate further increase in dosage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In congenital hypothyroidism, adequacy of replacement should be determined using both TSH and total- or free-T",
"     <sub>",
"      4",
"     </sub>",
"     . During the first 3 years of life, total- or free-T",
"     <sub>",
"      4",
"     </sub>",
"     should be maintained in the upper",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the normal range; this should result in normalization of the TSH. In some patients, TSH may not normalize due to a resetting of the pituitary-thyroid feedback as a result of",
"     <i>",
"      in utero",
"     </i>",
"     hypothyroidism. Monitor closely for cardiac overload, arrhythmias and aspiration from avid suckling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pediatric patients: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth, and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation, accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Suggested frequency for monitoring thyroid function tests: Every 1-2 months during the first year of life, every 2-3 months between ages 1-3 years, and every 3-12 months thereafter until growth is completed; repeat tests 2 weeks after any change in dosage.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F14941722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption>",
"      Thyroid Function Tests",
"     </caption>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Lab Parameters",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          4",
"         </sub>",
"         (thyroxine) serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.1-20.9 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-14 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.8-16.6 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 month to 1 year",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.5-16.0 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;1 year",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.0-12.0 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         Free thyroxine index (FTI)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.3-26.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 weeks",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.6-20.8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.4-17.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-12 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.1-14.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-6 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.7-13.3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;6 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.8-14.0",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          3",
"         </sub>",
"         serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Newborns",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-470 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-5 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-260 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-10 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90-240 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 years to Adult",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         70-210 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          3",
"         </sub>",
"         uptake",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35%-45%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         TSH serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Cord",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-22 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;40 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;25 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0-10 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14851209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The primary active compound is T",
"     <sub>",
"      3",
"     </sub>",
"     (triiodothyronine), which may be converted from T",
"     <sub>",
"      4",
"     </sub>",
"     (thyroxine) and then circulates throughout the body to influence growth and maturation of various tissues; exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization of glycogen stores and stimulates protein synthesis, increases basal metabolic rate.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F14851281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): ~3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14851210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: T",
"     <sub>",
"      4",
"     </sub>",
"     : 40% to 80%; T",
"     <sub>",
"      3",
"     </sub>",
"     : 95%; desiccated thyroid contains T",
"     <sub>",
"      4",
"     </sub>",
"     , T",
"     <sub>",
"      3",
"     </sub>",
"     , and iodine (primarily bound)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: T",
"     <sub>",
"      4",
"     </sub>",
"     : &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to triiodothyronine (active); ~80% T",
"     <sub>",
"      4",
"     </sub>",
"     deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     : Euthyroid: 6-7 days; Hyperthyroid: 3-4 days; Hypothyroid: 9-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T",
"     <sub>",
"      3",
"     </sub>",
"     : 2.5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: T",
"     <sub>",
"      4",
"     </sub>",
"     : 2-4 hours; T",
"     <sub>",
"      3",
"     </sub>",
"     : 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (major route of elimination); partially feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F14851214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/28/32197?source=see_link\">",
"      see \"Thyroid extract (desiccated thyroid): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thyroid replacement therapy is generally for life. Take in the morning before breakfast on an empty stomach. Do not take antacids or iron preparations within 4 hours of thyroid medication. Patients with diabetes should monitor their glucose levels (may increase need for oral hypoglycemics or insulin). Report chest pain, rapid heart rate, palpitations, heat intolerance, excessive sweating, increased nervousness, agitation, or lethargy.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14851215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Equivalent doses: The following statement on relative potency of thyroid products is included in a joint statement by American Thyroid Association (ATA), American Association of Clinical Endocrinologists (AACE) and The Endocrine Society (TES): For purposes of conversion, levothyroxine sodium (T",
"     <sub>",
"      4",
"     </sub>",
"     ) 100 mcg is usually considered equivalent to desiccated thyroid 60 mg, thyroglobulin 60 mg, or liothyronine sodium (T",
"     <sub>",
"      3",
"     </sub>",
"     ) 25 mcg. However, these are rough guidelines only and do not obviate the careful re-evaluation of a patient when switching thyroid hormone preparations, including a change from one brand of levothyroxine to another. Joint position statement is available at file://www.thyroid.org/professionals/advocacy/04_12_08_thyroxine.html.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al, \"Update of Newborn Screening and Therapy for Congenital Hypothyroidism,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(6):2290-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/57/22422/abstract-text/16740880/pubmed\" id=\"16740880\" target=\"_blank\">",
"        16740880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baskin HJ, Cobin RH, Duick DS, et al, \"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism,\"",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2002, 8(6):457-69.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhasin S, Wallace W, Lawrence JB, et al, &ldquo;Sudden Death Associated With Thyroid Hormone Abuse,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1981, 71(5):887-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/57/22422/abstract-text/7304660/pubmed\" id=\"7304660\" target=\"_blank\">",
"        7304660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86692 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22422=[""].join("\n");
var outline_f21_57_22422=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708983\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851204\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851338\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851211\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227333\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227320\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851212\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851280\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851205\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9954591\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227368\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851206\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851279\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851207\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300136\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851208\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227330\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12966353\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851213\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14941722\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851209\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851281\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851210\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851214\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851215\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86692\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86692|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9846?source=related_link\">",
"      Thyroid extract (desiccated thyroid): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/28/32197?source=related_link\">",
"      Thyroid extract (desiccated thyroid): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_57_22423="Clinical manifestations of vasculitic neuropathy";
var content_f21_57_22423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of vasculitic neuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22423/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22423/contributors\">",
"     Steven David Brass, MD, MPH, FRCP(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22423/contributors\">",
"     Simon M Helfgott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22423/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22423/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22423/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22423/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22423/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/57/22423/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitic diseases can affect any organ or tissue, including the peripheral nerves. When vasculitis affects the vasa nervorum, the results are often critical ischemia to peripheral nerves and potentially profound clinical sequelae.",
"   </p>",
"   <p>",
"    Vasculitic neuropathy is usually only one feature of a systemic condition that can involve the skin, lungs, kidneys, and other organs. As an example, the group of vasculitic disorders commonly associated with antineutrophil cytoplasmic antibodies (ANCA) (ie, granulomatosis with polyangiitis [Wegener&rsquo;s], microscopic polyangiitis, and Churg-Strauss syndrome) often cause vasculitic neuropathy. Polyarteritis nodosa (PAN) and mixed cryoglobulinemia are also prone to involve the peripheral nervous system.",
"   </p>",
"   <p>",
"    In a minority of patients with vasculitic neuropathy, the peripheral nervous system vasculitis occurs in isolation. In this setting, the disorder is referred to as nonsystemic vasculitic neuropathy or isolated peripheral nervous system vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in the absence of frank systemic vasculitis, nonsystemic vasculitic neuropathy can be a devastating illness, leading to severe functional disabilities from which some patients never recover fully. Because the regeneration of peripheral nerves may require months or years, the goal of therapy is to control the inflammation within the vasa nervorum as quickly as possible to prevent or minimize nerve damage.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations of vasculitic peripheral neuropathy. The diagnosis and treatment of vasculitic neuropathy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=see_link\">",
"     \"Diagnosis and treatment of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding of the initial pathogenetic events in vasculitic neuropathy remains incomplete. The pathogeneses of different vasculitic disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two well-established pathways leading to vasculitic nerve damage are immune complex deposition and cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune complex deposition &mdash; Immune complex deposition within the vessel walls activates monocytes to release proinflammatory cytokines, including those that stimulate neutrophil migration to the site of injury. The release of free radicals from neutrophils may contribute to nerve tissue damage.",
"      <br/>",
"      <br/>",
"      Immune complex-mediated injury is particularly relevant to the pathophysiology of mixed cryoglobulinemia and at least some cases of polyarteritis nodosa, particularly those associated with hepatitis B.",
"     </li>",
"     <li>",
"      Cell-mediated immunity &mdash; Cell-mediated immunity occurs when antigen presenting cells (including perhaps, in some cases, endothelial cells) present relevant antigens to circulating cytotoxic T cells. These interactions result in the production of proinflammatory cytokines, cell adhesion molecules, and other inflammatory mediators that cause neutrophils and lymphocytes to adhere to and destroy endothelial cells.",
"      <br/>",
"      <br/>",
"      Cell-mediated immunity is believed to be central to the pathophysiology of the ANCA-associated diseases, a group of disorders characterized by &ldquo;pauci-immune&rdquo; inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"       \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immune complex and cell-mediated immunity pathways are not mutually exclusive. As an example, in a study of hepatitis C virus-related mixed cryoglobulinemia, which is associated with prominent immune complex deposition, expression of mRNA was markedly increased for various T cell inflammatory mediators, including interferon gamma, tumor necrosis factor (TNF)-alpha, and macrophage inflammatory protein-1 alpha, in nerve biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional factors are under investigation in vasculitic neuropathy, including the cytokine, allograft inflammatory factor-1 (AIF-1), which appears to play a role in inflammatory nerve disease and in vascular smooth muscle cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory responses cause occlusion of the blood vessels that constitute the vasa nervorum. The histopathologic findings vary according to the particular type of disease causing the vasculitic neuropathy and the stage of therapy at which the biopsy is taken. Varying degrees of axonal loss occur, depending upon disease severity (",
"    <a class=\"graphic graphic_picture graphicRef77201 \" href=\"UTD.htm?15/57/16278\">",
"     picture 1",
"    </a>",
"    ). Polymorphonuclear cells are present in the infiltrates of the vessel wall in primary necrotizing vasculitis, while, in secondary vasculitis, the inflammatory infiltrate is mainly composed of mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic lymphocytic infiltration of the walls of blood vessels that supply affected peripheral nerves is typical of many diseases associated with vasculitic neuropathy (",
"    <a class=\"graphic graphic_picture graphicRef68618 \" href=\"UTD.htm?42/59/43958\">",
"     picture 2",
"    </a>",
"    ). In addition, eosinophilic infiltration of the vasa nervorum is present in Churg-Strauss syndrome (",
"    <a class=\"graphic graphic_picture graphicRef55115 \" href=\"UTD.htm?35/34/36387\">",
"     picture 3",
"    </a>",
"    ), a disorder in which up to 80 percent of patients are affected by vasculitic neuropathy. A leukocytoclastic vasculitis of the vasa nervorum may be seen early in the course.",
"   </p>",
"   <p>",
"    Histopathologic findings in vasculitic neuropathy include perivascular and transmural mononuclear cell infiltration of the epineural blood vessels. This inflammatory infiltrate, often comprised primarily of T cells and macrophages, may lead to fibrinoid necrosis of the blood vessel wall (",
"    <a class=\"graphic graphic_picture graphicRef81956 \" href=\"UTD.htm?7/8/7301\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/10\">",
"     10",
"    </a>",
"    ]. Many cases, particularly those in which immune complex deposition plays a primary role, demonstrate immunoglobulin and complement deposition within the vessel wall.",
"   </p>",
"   <p>",
"    DNA microarray analysis is a powerful tool for simultaneous analysis and comparison of gene products expressed in normal and diseased tissues; it has been used to demonstrate that several different types of genes related to immunity and to the regulation of vascular cells are upregulated in patients with vasculitic neuropathy. In one study, this technique was used to identify differentially expressed genes (DEGs) in nerve biopsy samples of chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy (VAS) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/11\">",
"     11",
"    </a>",
"    ]; genes upregulated in VAS included IGLJ3, IGHG3, IGKC, and IGL, which all function in B-cell selection or antigen recognition of B cells. Other upregulated genes included chemokines, such as CXCL9 and CCR2, as well as CPA3, a mast cell carboxypeptidase. In a second study, gene expression profile analysis revealed that, in peripheral nerve vasculitis, a prominent activation of immune response related genes, as well as genes involved in vascular proliferation, occurs, while genes inhibiting endothelial cell activation are down-regulated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patterns of nerve involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ischemic lesions accumulate randomly along the course of peripheral nerves. The clinical result is a pattern of damage to both sensory and motor nerves that is initially asymmetric, patchy, and distal. The longest nerves are affected first. Over time, the pattern may become more symmetric (",
"    <a class=\"graphic graphic_figure graphicRef75374 \" href=\"UTD.htm?43/39/44656\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nerve tissue within the watershed area of nutrient arteries may be particularly vulnerable to ischemic injury. Myelinated fibers are most sensitive to ischemia; however, with disease progression, unmyelinated fibers are also damaged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of vasculitic neuropathy can be divided into neurologic and non-neurologic features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms such as pain, paresthesia, numbness, and weakness are the presenting symptoms of vasculitic neuropathy. Symptoms may have an abrupt onset or may progress insidiously. The three patterns of nerve injury observed in vasculitic neuropathy are mononeuritis multiplex, distal polyneuropathy, and radiculopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plexopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mononeuritis multiplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the three types of presentation of vasculitic neuropathy, mononeuritis multiplex is the most specific for the diagnosis of vasculitis. Mononeuritis multiplex is defined as nerve damage in two or more named nerves in separate parts of the body. &ldquo;Wrist-drop,&rdquo; for example, is caused by infarction of the radial nerve, and &ldquo;foot-drop&rdquo; is caused by damage to either the sciatic or the peroneal nerve (",
"    <a class=\"graphic graphic_picture graphicRef59168 \" href=\"UTD.htm?7/43/7871\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because nerve length affects the frequency of clinical involvement by vasculitic neuropathy and because the longest nerves in the body are affected first, foot-drop is the most common manifestation of mononeuritis multiplex. Patients are often unaware of dorsiflexion weakness until it is demonstrated by the examiner. Foot-drop may also be evident through observation of the patient in ambulation; patients with tibialis anterior weakness must raise their knee on the affected side high in order to avoid tripping over the weakened foot, leading to a &ldquo;foot-slapping&rdquo; gait.",
"   </p>",
"   <p>",
"    Other peripheral nerves may be affected, including the tibial, ulnar, and median nerves. Nerve infarction eventually leads to muscle wasting, which, in many cases, is permanent (",
"    <a class=\"graphic graphic_picture graphicRef51613 \" href=\"UTD.htm?27/14/27872\">",
"     picture 6",
"    </a>",
"    ). If mononeuritis multiplex progresses, more nerves may become involved, eventually leading to a more symmetric or confluent appearance to the pattern of nerve dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Polyneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distal, symmetrical polyneuropathy is more common in vasculitic neuropathy than was previously believed, and asymmetric presentations have been described. Electromyography with nerve conduction velocity testing often reveals greater asymmetry to the process than is appreciated on clinical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=see_link\">",
"     \"Diagnosis and treatment of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Radiculopathy and/or plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiculopathies and neural plexopathies have been documented in association with polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/13\">",
"     13",
"    </a>",
"    ]. Dermatomal sensory impairment is characteristic of radicular involvement. In contrast, symptoms or findings that cannot be localized to a single peripheral nerve or nerve root should raise suspicion of a brachial or lumbar plexopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H41#H41\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Brachial plexopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link&amp;anchor=H37#H37\">",
"     \"Overview of lower extremity peripheral nerve syndromes\", section on 'Lumbosacral plexopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Non-neurologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constitutional symptoms such as fever, malaise, and weight loss are nonspecific features related to the effects of circulating cytokines and other biologic mediators. These symptoms are more likely to occur in patients with a systemic rather than nonsystemic vasculitic neuropathy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Nonsystemic vasculitic neuropathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific organ involvement beyond the peripheral nerves also may provide a clue to the presence of an underlying disorder. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpable purpura or skin ulcers are found in primary vasculitides associated with small- or medium-vessel vasculitis (eg, hypersensitivity vasculitis or granulomatosis with polyangiitis [Wegener&rsquo;s]).",
"     </li>",
"     <li>",
"      Respiratory tract involvement is consistent with some form of ANCA-associated vasculitis (eg, destructive upper airway lesions in granulomatosis with polyangiitis [Wegener&rsquo;s]; asthma, allergic rhinitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nasal polyps in Churg-Strauss; and alveolar hemorrhage in all forms).",
"     </li>",
"     <li>",
"      Intestinal angina may signal the presence of medium-vessel mesenteric vasculitis, as found in polyarteritis nodosa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SYSTEMIC DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major forms of systemic disease that are associated with vasculitic neuropathy include both certain vasculitides and connective tissue disorders. In a review of 106 patients with vasculitic neuropathy compiled at one center over a period of 28 years, the major diagnostic categories were [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasculitis (72 patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Churg-Strauss syndrome: 22",
"     </li>",
"     <li>",
"      Polyarteritis nodosa: 19",
"     </li>",
"     <li>",
"      Granulomatosis with polyangiitis (Wegener&rsquo;s): 14",
"     </li>",
"     <li>",
"      Microscopic polyangiitis: 8",
"     </li>",
"     <li>",
"      Unclassified systemic vasculitis: 6",
"     </li>",
"     <li>",
"      Cryoglobulinemia: 2",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis): 1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Connective tissue disease (16 patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rheumatoid arthritis: 12",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus: 4",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsystemic vasculitic neuropathy (11 patients)",
"     </li>",
"     <li>",
"      Other (7 patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Paraneoplastic: 4",
"     </li>",
"     <li>",
"      Infection: 3",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Systemic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the vasculitides are associated more closely than others with vasculitic neuropathy. Those that involve arterioles and small- and medium-sized arteries are the types of vasculitis most frequently associated with neuropathy. In contrast, pure small-vessel forms of vasculitis, such as hypersensitivity vasculitis, and pure large-vessel forms of disease, such as Takayasu arteritis, are seldom, if ever, associated with vasculitic neuropathy. As a result, the occurrence of vasculitic neuropathy in patients with these conditions should trigger a reconsideration of the underlying diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     ANCA-associated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nervous system involvement is noted in approximately 15 percent of patients with granulomatosis with polyangiitis (Wegener&rsquo;s), in 70 percent of those with microscopic polyangiitis, and in 80 percent of those with Churg-Strauss syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 50 and 75 percent of patients with polyarteritis nodosa have some type of peripheral nervous system involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/14\">",
"     14",
"    </a>",
"    ]. Associated clinical features may include cutaneous ulcers, digital ischemia, and microaneurysm formation visible on conventional angiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"UTD.htm?35/54/36705\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cryoglobulinemic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies have detected peripheral neuropathy in approximately two-thirds of patients with mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In these patients, circulating cryoglobulins deposit in the vasa nervorum. The neuropathy typically affects the distal extremities in a symmetric fashion, with predominantly sensory involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/18\">",
"     18",
"    </a>",
"    ]. Associated clinical features seen in patients with vasculitic neuropathy and cryoglobulinemic vasculitis include palpable purpura, skin ulcers, and arthralgias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of hepatitis C-associated cryoglobulinemia should be considered in patients who present with unexplained peripheral neuropathies. Several studies have confirmed a high percentage of these patients having previously undiagnosed hepatitis C infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. However, vasculitic neuropathy related to cryoglobulinemia is unlikely in the absence of signs of cutaneous vasculitis (ie, purpura, hyperpigmentation from previous episodes of purpura,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin ulcers).",
"   </p>",
"   <p>",
"    Cryoglobulinemic vasculitis has been reported as a complication of HIV infection. Vasculitic neuropathy may be a manifestation of HIV infection itself or of opportunistic infections in late-stage",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\", section on 'Mononeuritis multiplex'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitic neuropathies can present in association with connective tissue diseases such as systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/21-24\">",
"     21-24",
"    </a>",
"    ], rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/25\">",
"     25",
"    </a>",
"    ], and Sj&ouml;gren&rsquo;s syndrome (",
"    <a class=\"graphic graphic_table graphicRef70269 \" href=\"UTD.htm?31/22/32108\">",
"     table 1",
"    </a>",
"    ). Peripheral neuropathy associated with each of these disorders is discussed in more detail elsewhere, and the following is a brief summary of some salient points:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Lupus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three forms of lupus neuropathy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=see_link\">",
"     \"Neurologic manifestations of systemic lupus erythematosus\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common is an acute or subacute symmetric sensory or motor polyneuropathy. Most patients present with decreased sensation that initially involves the lower extremities.",
"     </li>",
"     <li>",
"      There may be single or multiple mononeuropathies occurring in isolation or simultaneously. These manifestations may be superimposed on a symmetric distal polyneuropathy.",
"     </li>",
"     <li>",
"      The rarest form of peripheral neuropathy is an ascending motor radiculoneuropathy that resembles Guillain-Barr&eacute; syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathy occurs in approximately 10 percent of patients with RA when assessed using electrophysiologic criteria. The most common presentation is a slowly progressive, distal, symmetric sensorimotor polyneuropathy. In the majority of cases, detailed evaluation reveals that the underlying pathophysiology of this nerve dysfunction is related to vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11129?source=see_link\">",
"     \"Neurologic manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most concerning form is the vasculitic neuropathy that occurs in rheumatoid vasculitis. This typically afflicts patients with seropositive, destructive joint disease at a stage when the arthritis is relatively &ldquo;burnt-out.&rdquo; Other extraarticular manifestations such as scleritis, pericarditis, cutaneous ulcerations, and mesenteric vasculitis often accompany the vasculitic neuropathy, which demonstrates an acute mononeuritis multiplex pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy occurs in approximately 10 percent of patients with Sj&ouml;gren&rsquo;s syndrome. This is usually a symmetric, sensorimotor polyneuropathy in which the sensory features, such as dysesthesias, predominate. Histopathologic features including perivascular cellular infiltration and axonal neuropathy suggest a vasculitic etiology in some cases, but mononuclear cell infiltration more often occurs in the absence of documented vasculitis. Autonomic involvement and cranial neuropathies also can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\", section on 'Peripheral nervous system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NONSYSTEMIC VASCULITIC NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nonsystemic vasculitic peripheral neuropathy comprise a minority of those with vasculitic neuropathy. This was illustrated in a series of 71 patients with biopsy-proven vasculitic neuropathy, of which 22 (31 percent) had no other organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with vasculitis that is localized to the peripheral nervous system at presentation must be followed closely for signs of other organ involvement. Some eventually develop vasculitis in other organs and are then diagnosed with a systemic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22423/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasculitic neuropathy results from inflammation in the blood vessel walls of the vasa nervorum. The three patterns of nerve injury in vasculitic neuropathy are mononeuritis multiplex, distal polyneuropathy, and radiculopathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plexopathy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patterns of nerve involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical result is typically a pattern of damage to both sensory and motor nerves that is asymmetric, patchy, and distal. The longest nerves in the body (those in lower extremities) are affected first. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vasculitic neuropathy most often occurs in the context of a systemic disease, usually a form of vasculitis or a connective tissue disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Systemic disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less often, vasculitic neuropathy presents in an isolated fashion, a presentation called nonsystemic vasculitic neuropathy or isolated peripheral nervous system vasculitis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Nonsystemic vasculitic neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/1\">",
"      Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain 1987; 110 ( Pt 4):843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/2\">",
"      Collins MP, Periquet MI. Non-systemic vasculitic neuropathy. Curr Opin Neurol 2004; 17:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/3\">",
"      Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain 1996; 119 ( Pt 5):1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/4\">",
"      Mathew L, Talbot K, Love S, et al. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM 2007; 100:41.",
"     </a>",
"    </li>",
"    <li>",
"     Ransohoff R, Beneviste E, Cadavid D. Vascultis and vasculopathies of the nervous system. In: Continiuum neuroimmunology, First Edition, Mancall EL, Cascino TL, Devereaux MW, Lambert AL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.146.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/6\">",
"      Hawke SH, Davies L, Pamphlett R, et al. Vasculitic neuropathy. A clinical and pathological study. Brain 1991; 114 ( Pt 5):2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/7\">",
"      Saadoun D, Bieche I, Maisonobe T, et al. Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 2005; 52:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/8\">",
"      Broglio L, Erne B, Tolnay M, et al. Allograft inflammatory factor-1: a pathogenetic factor for vasculitic neuropathy. Muscle Nerve 2008; 38:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/9\">",
"      Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol 2005; 252:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/10\">",
"      Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/11\">",
"      Steck AJ, Kinter J, Renaud S. Differential gene expression in nerve biopsies of inflammatory neuropathies. J Peripher Nerv Syst 2011; 16 Suppl 1:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/12\">",
"      Kinter J, Broglio L, Steck AJ, et al. Gene expression profiling in nerve biopsy of vasculitic neuropathy. J Neuroimmunol 2010; 225:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/13\">",
"      Allan SG, Towla HM, Smith CC, et al. Painful brachial plexopathy: an unusual presentation of polyarteritis nodosa. Postgrad Med J 1982; 58:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/14\">",
"      Pagnoux C, Guillevin L. Peripheral neuropathy in systemic vasculitides. Curr Opin Rheumatol 2005; 17:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/15\">",
"      Suppiah R, Hadden RD, Batra R, et al. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2011; 50:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/16\">",
"      Garcia-Bragado F, Fernandez JM, Navarro C, et al. Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 1988; 45:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/17\">",
"      Gemignani F, Melli G, Inglese C, Marbini A. Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients. J Peripher Nerv Syst 2002; 7:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/18\">",
"      Gemignani F, Brindani F, Alfieri S, et al. Clinical spectrum of cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 2005; 76:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/19\">",
"      Griffin JW. Vasculitic neuropathies. Rheum Dis Clin North Am 2001; 27:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/20\">",
"      Said G. Vasculitic neuropathy. Curr Opin Neurol 1999; 12:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/21\">",
"      McCombe PA, McLeod JG, Pollard JD, et al. Peripheral sensorimotor and autonomic neuropathy associated with systemic lupus erythematosus. Clinical, pathological and immunological features. Brain 1987; 110 ( Pt 2):533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/22\">",
"      McNicholl JM, Glynn D, Mongey AB, et al. A prospective study of neurophysiologic, neurologic and immunologic abnormalities in systemic lupus erythematosus. J Rheumatol 1994; 21:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/23\">",
"      Omdal R, Mellgren SI, Husby G, et al. A controlled study of peripheral neuropathy in systemic lupus erythematosus. Acta Neurol Scand 1993; 88:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/24\">",
"      Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006; 85:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/25\">",
"      Pu&eacute;chal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995; 38:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/26\">",
"      Kararizou E, Davaki P, Karandreas N, et al. Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol 2005; 32:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22423/abstract/27\">",
"      Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 2010; 15:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8236 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22423=[""].join("\n");
var outline_f21_57_22423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patterns of nerve involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mononeuritis multiplex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Radiculopathy and/or plexopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Non-neurologic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SYSTEMIC DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Systemic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - ANCA-associated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cryoglobulinemic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Lupus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NONSYSTEMIC VASCULITIC NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8236|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/54/36705\" title=\"diagnostic image 1\">",
"      Renal arteriogram in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8236|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/39/44656\" title=\"figure 1\">",
"      Progression vasc neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8236|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/57/16278\" title=\"picture 1\">",
"      Nerve biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/59/43958\" title=\"picture 2\">",
"      Lymph infiltr nerve vessel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/34/36387\" title=\"picture 3\">",
"      Eosinophils in vessel wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/8/7301\" title=\"picture 4\">",
"      Fibrinoid nec flood vessel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/43/7871\" title=\"picture 5\">",
"      Wrist drop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/14/27872\" title=\"picture 6\">",
"      Mononeuritis multiplex MPA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8236|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/22/32108\" title=\"table 1\">",
"      Vasculitic periph neuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=related_link\">",
"      Diagnosis and treatment of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=related_link\">",
"      Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11129?source=related_link\">",
"      Neurologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_57_22424="Diagnosis and treatment of delayed puberty";
var content_f21_57_22424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of delayed puberty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22424/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Nelly Pitteloud, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22424/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/57/22424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed puberty is defined clinically by the absence or incomplete development of secondary sexual characteristics bounded by an age at which 95 percent of children of that sex and culture have initiated sexual maturation. The clinical staging of puberty is performed by the criteria established by James Tanner. According to the National Center for Health Statistics, the upper 95th percentile in the United States for age for boys is 14 (ie, an increase in testicular size being the first sign) and for girls is 12 (breast development being the first sign) (",
"    <a class=\"graphic graphic_table graphicRef55329 \" href=\"UTD.htm?8/1/8220\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed puberty usually results from inadequate gonadal steroid secretion which, in turn, is most often caused by a defective gonadotropin secretion from the anterior pituitary, due to defective production of gonadotropin-releasing hormone (GnRH) from the hypothalamus, the key functional defect in patients with constitutional delay of puberty. It can, however, also be caused by a variety of hypothalamic, pituitary, and gonadal disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17171365\">",
"    <span class=\"h1\">",
"     PRIMARY VERSUS SECONDARY HYPOGONADISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dating back to the time of Fuller Albright and his colleagues, it has been useful to classify the syndrome pathophysiologically according to the circulating levels of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (",
"    <a class=\"graphic graphic_table graphicRef62372 \" href=\"UTD.htm?1/38/1645\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High serum concentrations of LH and FSH are associated with various causes of gonadal disease, called primary hypogonadism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      defects in their receptors on the membrane of the gonadal cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"       \"Causes of primary hypogonadism in males\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=see_link\">",
"       \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low or normal serum LH and FSH concentrations are associated with various causes of diminished GnRH-induced gonadotropin secretion, called secondary hypogonadism. This defect can be because of hypothalamic dysfunction (either anatomic or functional), hypopituitarism, hypothyroidism, or hyperprolactinemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"       \"Causes of secondary hypogonadism in males\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Impaired secretion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    action of hypothalamic GnRH typically is the underlying cause of secondary hypogonadism. It can be functional in origin (as in constitutional delay of puberty, chronic illness, excessive exercise, malnutrition, and stress) or related to associated pathology (as with hypothalamic and pituitary tumors, especially craniopharyngioma), or genetic causes (hypogonadotropic hypogonadism with anosmia [Kallmann&rsquo;s syndrome], or idiopathic hypogonadotropic hypogonadism [IHH]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of these diagnoses has been examined in a retrospective study of 232 adolescents (158 males, 74 females) presenting to an academic center [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constitutional delay of puberty was the presumed cause in 53 percent of subjects (63 percent of males and 30 percent of females).",
"     </li>",
"     <li>",
"      Delayed but spontaneous pubertal development (functional hypogonadotropic hypogonadism) occurred in 19 percent. This may be associated with an underlying condition such as growth hormone deficiency or poor nutrition, or heterozygous mutations in genes associated with congenital GnRH deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypogonadotropic hypogonadism in 12 percent, which is often but not always permanent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypergonadotropic hypogonadism (ie, primary gonadal failure) in 13 percent.",
"     </li>",
"     <li>",
"      Unclassified, 3 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because most of these disorders have in common a functional defect in GnRH secretion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its action, no single test except for observation over time reliably distinguishes patients with constitutional delay of puberty (who will eventually progress spontaneously through puberty) from patients with other causes of delayed puberty, particularly congenital GnRH deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In addition, because 10 to 15 percent of cases of well-documented isolated GnRH deficiency undergo spontaneous reversals after being treated with sex steroids, these distinctions between constitutional delay of puberty and isolated GnRH deficiency are becoming less absolute [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, a complete history and physical examination should precede any biochemical testing or imaging studies are performed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history helps determine whether pubertal development is totally absent or had started but then \"stalled.\" Thus, assessment of the patient's growth pattern up to the time of evaluation is critical. Patients with constitutional delay have delayed (not stalled) growth, adrenarche, and sexual development in temporal association with declining growth velocity, delayed skeletal maturation, and delayed adrenal androgen maturation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other important issues in the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nutritional habits, exercise intensity, prior medical illness, or medication usage that may delay the onset or slow the tempo of puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/7\">",
"       7",
"      </a>",
"      ]. Delays in sexual maturation and growth velocity often can be the first clinical signs of underlying disorders, such as inflammatory bowel disease, hypothyroidism, or psychosocial deprivation.",
"     </li>",
"     <li>",
"      The presence of associated congenital abnormalities (eg, midline defects, cryptorchidism, skeletal abnormalities like cleft",
"      <span class=\"nowrap\">",
"       lip/palate,",
"      </span>",
"      or scoliosis) suggests congenital GnRH deficiency (particularly resulting from mutations in the fibroblast growth factor [FGF] signaling pathway), with or without other hypothalamic defects. Neurologic symptoms such as headache, visual disturbances, anosmia, dyskinesia, seizures, and intellectual disability (mental retardation) strongly suggest a central nervous system (CNS) disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"       \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A positive family history of either constitutional delay of puberty or congenital GnRH deficiency can be a useful clue. Indeed, delayed puberty has a significant genetic basis often demonstrating an autosomal dominant mode of inheritance, with or without incomplete penetrance [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/8\">",
"       8",
"      </a>",
"      ]. Furthermore, higher rates of constitutional delay of puberty have been observed in families with congenital GnRH deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/9\">",
"       9",
"      </a>",
"      ]. However, this finding is nonspecific and is common in both constitutional delay and idiopathic hypogonadotropic hypogonadism. As examples, mutations in FGF receptor 1 (FGFR1) and CHD7 demonstrate an autosomal dominant mode of inheritance, whereas KAL1 and NR0B1 (DAX1) demonstrate an X-linked pattern within a pedigree [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/10\">",
"       10",
"      </a>",
"      ]. TAC3 or TAC3R mutations are associated with microphallus and cryptorchidism in males, and spontaneous reversal during adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"       \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of an absent or abnormal sense of smell (anosmia or hyposmia) strongly suggests Kallmann syndrome, which is associated with a number of genes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/10,12,13\">",
"       10,12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link&amp;anchor=H372819954#H372819954\">",
"       \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful assessments of height, weight, arm span, and secondary sex characteristics are the most important aspects of the physical examination. Early signs of sexual development unnoticed by the patient (such as testicular growth) may permit reassurance and avoidance of an otherwise costly evaluation in the otherwise normal child. Often serial height and testicular measurements made over one or two years will help clarify the diagnosis.",
"   </p>",
"   <p>",
"    Both the standing height and the arm span should be measured. An arm span exceeding the height by more than 5 cm (ie, eunuchoidal body habitus) suggests delayed epiphyseal closure secondary to hypogonadism. The height should be plotted on growth charts that include normal growth patterns with centiles or standard deviation scores (",
"    <a class=\"graphic graphic_figure graphicRef74388 \" href=\"UTD.htm?16/39/17023\">",
"     figure 1",
"    </a>",
"    ) to place the current height in the proper developmental context and to allow comparison with both current and subsequent bone age determination. The height velocity should be carefully documented for at least six months.",
"   </p>",
"   <p>",
"    Secondary sexual characteristics should be staged according to the Tanner criteria, also called sexual maturity ratings (SMR) (",
"    <a class=\"graphic graphic_table graphicRef55329 \" href=\"UTD.htm?8/1/8220\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/14\">",
"     14",
"    </a>",
"    ]. In girls, this may include determining the presence of a uterus typically by an abdominal ultrasound if the patient is virginal or by transvaginal techniques that are far preferable to pelvic examination in this population; the uterus is absent in patients with androgen insensitivity and disorders of the M&uuml;llerian duct system.",
"   </p>",
"   <p>",
"    In boys, testicular size should be measured by a Prader orchidometer. The earliest signs of pubertal development are a testicular volume of greater than or equal to 4 mL in boys (",
"    <a class=\"graphic graphic_figure graphicRef60225 \" href=\"UTD.htm?43/46/44781\">",
"     figure 2",
"    </a>",
"    ) (corresponding to about 2.0 to 3.1 cm in testicular length), and the appearance of breast buds in girls. If either is present, normal spontaneous puberty can be anticipated in more than 95 percent of patients and the family can be reassured for the most part. However, longitudinal follow-up is essential since some children with genetic causes of idiopathic hypogonadotropic hypogonadism can exhibit stuttering onset or cessation after some initial signs of pubertal development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link&amp;anchor=H4#H4\">",
"     \"Normal puberty\", section on 'Sexual maturity rating (Tanner stages)'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Particular attention also should be paid to the symmetry of the testes as gonadal tumors can occur in several intersex disorders presenting at puberty with asymmetrical gonadal development and defects in sexual maturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An x-ray of the left hand and wrist to evaluate bone age may be obtained at the initial visit to assess skeletal maturation and repeated over time if needed. The baseline x-ray provides valuable information about the relationship between chronologic age and skeletal maturation, the potential for future skeletal growth, and allows a preliminary prediction of adult height. Patients with constitutional delay of puberty typically have bone ages of 12 to 13.5 years but rarely progress beyond this age without the presence of pubertal levels of gonadal steroids because sex steroids are required for epiphyseal closure.",
"   </p>",
"   <p>",
"    Depending upon the clinical findings and the results of the initial biochemical work-up, other imaging studies may be indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic or testicular ultrasonography should be performed when an ovarian or testicular mass is detected on the physical examination.",
"     </li>",
"     <li>",
"      Pelvic ultrasound also may be performed in girls with delayed puberty to determine the presence or absence of a uterus.",
"     </li>",
"     <li>",
"      Head MRI should be ordered if associated neurologic symptoms or signs suggest a central process, or if the laboratory studies are consistent with hypothalamic or pituitary disease. In addition, clinicians may request particular imaging to assess the presence or",
"      <span class=\"nowrap\">",
"       hypoplasia/absence",
"      </span>",
"      of the olfactory bulb, nerves, and tract which can provide insight into the possibility of Kallmann syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033740\">",
"    <span class=\"h3\">",
"     General evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation should be directed at the possibility of nutritional disorders, occult chronic illness (eg, chronic inflammatory bowel disease, anorexia nervosa, or hepatic disease) that may affect the hypothalamic GnRH pulse generator [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/15\">",
"     15",
"    </a>",
"    ], and hormonal abnormalities. Initial screening should include a complete blood count, erythrocyte sedimentation rate, blood urea nitrogen (BUN), creatinine, and liver function tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033733\">",
"    <span class=\"h3\">",
"     Hormonal tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hormonal evaluation should include the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Random measurements of serum LH and FSH, together with estradiol (females) or testosterone (males), should be obtained to distinguish between primary and secondary hypogonadism. These measurements do not need to be corrected or scaled for age, but they do depend critically on adequate normative data from the reference laboratory. By adolescence, patients with primary hypogonadism have serum gonadotropin concentrations that are elevated and usually easily distinguished from their normal peers; this is particularly true for FSH levels which provide the greatest discriminate value at this time.",
"      <br/>",
"      <br/>",
"      On the other hand, baseline serum gonadotropin values are typically low in both constitutional delay of puberty and congenital GnRH deficiency. Ultrasensitive immunofluorometric assays for LH and FSH may eventually prove capable of distinguishing between the low gonadotropin levels of patients with constitutional delay versus the undetectable levels in GnRH-deficient patients; however, these assays have not yet been widely validated for the screening of truly GnRH-deficient patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GnRH stimulation testing is not recommended because it does not help distinguish between these disorders as there is significant overlap of LH and FSH responses between the two groups of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. Several reports have suggested stimulation tests with other GnRH agonists such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/10/17573?source=see_link\">",
"       buserelin",
"      </a>",
"      are better at differentiating GnRH-deficient patients from those with constitutional delay [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. In most patients, however, the distinction between congenital GnRH deficiency and constitutional delay of puberty remains ambiguous and can be resolved only with time and serial observations. In some patients, therapy may be initiated prior to determining the diagnosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A random measurement of serum prolactin should be obtained to detect hyperprolactinemia, which can present clinically as \"stalled\" puberty. An elevated prolactin level can result from a lactotroph adenoma (prolactinoma) or from any hypothalamic or pituitary disorder that interrupts hypothalamic inhibition of prolactin secretion. Hyperprolactinemia (unless clearly related to a prolactin-raising medication) should be followed by CNS imaging of the hypothalamus and the pituitary region by head MRI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"       \"Causes of hyperprolactinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"       \"Causes, presentation, and evaluation of sellar masses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tests for hypothyroidism, which delays puberty by as yet unknown mechanisms, should be obtained, particularly if growth velocity has suddenly slowed and the bone age is markedly delayed. An elevated serum concentration of thyroid-stimulating hormone (TSH) is the hallmark of primary hypothyroidism; however, the values are usually normal or low when hypothyroidism is a result of hypothalamic or pituitary disease. As a result, serum free T4 should be measured if CNS disease is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"       \"Laboratory assessment of thyroid function\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22059968\">",
"    <span class=\"h3\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the clinical findings and the results of the hormonal testing, the evaluation can then be completed with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of adrenal androgens, especially serum dehydroepiandrosterone sulfate (DHEA-S), a sex steroid almost exclusively of adrenal origin, may help to distinguish between congenital GnRH deficiency and constitutional delay of puberty. Patients with GnRH deficiency are more likely to have normal adrenal maturation (ie, adrenarche) and normal serum concentrations of adrenal androgens than patients with delayed puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/22\">",
"       22",
"      </a>",
"      ], but the values in the two groups often overlap.",
"     </li>",
"     <li>",
"      A karyotype or comparative genomic hybridization (CGH) array should be performed in every patient with primary hypogonadism to evaluate the possibility of Klinefelter syndrome in boys and Turner syndrome in girls. These patients rarely present with delayed puberty as an isolated finding because almost all patients have other physical findings that suggest these diseases. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4873651\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a specific underlying disorder can be identified (",
"    <a class=\"graphic graphic_table graphicRef62372 \" href=\"UTD.htm?1/38/1645\">",
"     table 2",
"    </a>",
"    ), therapy should be targeted at that disorder. As examples, thyroid hormone replacement in hypothyroidism or dopamine agonist treatment of lactotroph adenomas, and excision of craniopharyngiomas can result in prompt institution of sexual maturation in the appropriate clinical circumstances. In most patients, however, the distinction between congenital GnRH deficiency and constitutional delay of puberty remains uncertain, and can be resolved only with serial observations. &nbsp;",
"   </p>",
"   <p>",
"    In view of these diagnostic difficulties, the initial therapeutic approach is similar for both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The two major options are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Watchful waiting\" with reassurance and psychological support for the patient and family.",
"     </li>",
"     <li>",
"      Administration of gonadal steroids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Short-term hormonal therapy with testosterone in boys and with estrogen in girls may be appropriate when the pubertal delay is severe or the patient's psychosocial concerns about the delay play a prominent role that cannot be addressed by reassurance and education alone.",
"   </p>",
"   <p>",
"    Except under unusual circumstances, therapy should be restricted to",
"    <strong>",
"     boys older than 14 years",
"    </strong>",
"    and",
"    <strong>",
"     girls older than 12 years",
"    </strong>",
"    who show few or no signs of puberty and are expressing considerable anxiety about their delay. The short-term use of exogenous testosterone in boys or estrogen in girls does not appear to have any long-term sequelae except for the potential of skeletal maturation that might result in some loss of adult height.",
"   </p>",
"   <p>",
"    Short-term therapeutic goals include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attainment of age-appropriate secondary sex characteristics to ameliorate the patient's concern about",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      appearance relative to peers, a particular problem for boys in communal settings that require disrobing such as in showers and gym classes but one that occurs to some degree in both sexes.",
"     </li>",
"     <li>",
"      Induction of a growth spurt",
"      <strong>",
"       without",
"      </strong>",
"      inducing premature epiphyseal closure. This goal requires frequent (eg, every six months) longitudinal monitoring of bone age during therapy.",
"     </li>",
"     <li>",
"      Potential induction of a \"reversal\" of their GnRH deficiency, whether congenital or functional; sex steroid hormone therapy has been demonstrated to induce puberty even in cases in which the GnRH deficiency is of a genetic etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The long-term goals of therapy, if the diagnosis proves to be isolated GnRH deficiency, are to maintain the serum concentrations of sex steroids within the normal adult range and, eventually, to induce fertility if and when the patient desires. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=see_link\">",
"     \"Induction of fertility in men with secondary hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Testosterone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone can be administered by several routes, and patient preferences should be consulted. An oral preparation of testosterone undecanoate is available in some countries, but the levels of testosterone achieved with this preparation seem to be slightly more erratic. The use of testosterone gel transdermally seems appealing because of its efficacy and convenience in adult males with hypogonadism but it has not yet been widely tested or approved in males younger than age 18 years. Most studies in adolescents have been done with low dose intramuscular injections of testosterone esters [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/25-34\">",
"     25-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H3#H3\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Testosterone preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testosterone doses should initially be relatively low (eg, 50 mg of testosterone enanthate or testosterone cypionate once a month). Such a dose (about 15 to 25 percent of the adult dose) is usually sufficient to achieve early virilization and growth over time (ie, three to six months), without unduly advancing epiphyseal maturation (bone age). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One approach is to administer testosterone enanthate (50 mg IM Q month) for six months and then to reassess endogenous gonadal function and size six months later. Spontaneous pubertal development is then often evident and organic disease is excluded by testicular enlargement (which, if present, implies gonadotropin stimulation) and increasing testosterone concentrations after the cessation of therapy.",
"   </p>",
"   <p>",
"    Although some reports indicate that delayed onset of puberty may compromise adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/32\">",
"     32",
"    </a>",
"    ], most studies indicate that height is not adversely affected, particularly if the duration of sex steroid therapy is brief [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/24-27,30,33\">",
"     24-27,30,33",
"    </a>",
"    ]. The use of low doses of androgens for limited periods of time maximizes the likelihood that the boy will reach his \"predicted\" final height unless the diagnosis of GnRH deficiency is clearly established.",
"   </p>",
"   <p>",
"    In one report, for example, 15 boys with constitutional delay of puberty were treated with testosterone enanthate (50",
"    <span class=\"nowrap\">",
"     mg/month)",
"    </span>",
"    for a mean of 1.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/24\">",
"     24",
"    </a>",
"    ]. Mean height velocity increased from the 3rd percentile for mean bone age to above the 90th percentile and mean testicular volume rose from 5.9 to 11.3 mL during therapy, this latter observation suggesting the course of androgen therapy was accompanied by the occurrence of spontaneous puberty. Skeletal maturation increased only in the boys with an initial bone age below the group mean. After cessation of therapy, bone age and sexual development proceeded normally and the boys ultimately achieved their predicted mean height. Similar results have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/24-27,30,33\">",
"     24-27,30,33",
"    </a>",
"    ]. Thus, it is unusual for a boy with constitutional delay of puberty to require more than two courses of androgen therapy before spontaneous puberty occurs.",
"   </p>",
"   <p>",
"    Boys with hypogonadotropic hypogonadism, in contrast, typically demonstrate little or no pubertal development with low-dose testosterone and any pubertal progress they have made stops with cessation of therapy. After the age of 18 in these patients without any organic or obvious pathologic causes, congenital GnRH deficiency is the most likely diagnosis. However, approximately ten percent of the GnRH-deficient patients appear to undergo a spontaneous reversal later in life after sex steroid exposure. This reversal is heralded by testicular growth or the ability to sustain a normal testosterone concentration off of treatment or following a missed prescription refill [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22424/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In girls, estrogen may be given orally or transdermally, initially at doses below those used for replacement therapy in adults. Some experts start with conjugated estrogens 0.3 mg daily, approximately one-half of the dose used in adults. But the trend has been to start with even lower doses, such as oral micronized estradiol 0.25",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or transdermal estradiol 14",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (the lowest available transdermal dose). In women with Turner syndrome, some experts suggest either cutting the transdermal patch, or wearing the patch only at night to administer even lower doses of transdermal estrogen (6.25",
"    <span class=\"nowrap\">",
"     micrograms/day)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef62742 \" href=\"UTD.htm?27/55/28540\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\", section on 'Estrogen therapy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    These doses are below that required to induce menstruation. We increase the estrogen dose gradually over two years as outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef62742 \" href=\"UTD.htm?27/55/28540\">",
"     table 3",
"    </a>",
"    ). A progestin should not be added until there is substantial breast development that is not solely confined to the areolae, and full contour breast growth has plateaued as premature initiation of progestin therapy can compromise ultimate breast growth.",
"   </p>",
"   <p>",
"    We add cyclic progestin therapy after two years of estrogen or when breakthrough bleeding occurs on unopposed estrogen. Our first choice for progestin therapy is oral micronized progesterone 200 mg days 1 to 12 of the calendar month.",
"   </p>",
"   <p>",
"    Once breast growth has plateaued during serial evaluation and menstruation been established, estrogen therapy can be discontinued intermittently for one- to three-month periods to determine if spontaneous menstruation occurs, which should happen in girls with constitutional delay. As in boys, persistent hypogonadism beyond age 18 is highly suggestive of congenital GnRH deficiency. At this time, full adult replacement therapy with both estrogen and progesterone should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Growth hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of growth hormone therapy in patients without documented growth hormone deficiency is controversial. Serum growth hormone and IGF-I concentrations are usually low in patients with constitutional delay of puberty and increase in response to testosterone or estrogen therapy. Patients with congenital GnRH deficiency are typically not growth hormone-deficient and do not benefit from growth hormone therapy since sex steroids evoke these normal increases in their growth axis. Although the administration of growth hormone is less likely to induce epiphyseal closure than sex steroids and may therefore add to adult height, children with delayed puberty grow well when treated with sex steroids alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=see_link\">",
"       \"Patient information: Late puberty (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17171410\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed puberty is defined clinically by the absence or incomplete development of secondary sexual characteristics bounded by an age at which 95 percent of children of that sex and culture have initiated sexual maturation. In the United States, the upper 95th percentile in the United States for boys to initiate puberty is 14 (an increase in testicular size being the first sign) and for girls is 12 (breast development being the first sign) (",
"      <a class=\"graphic graphic_table graphicRef55329 \" href=\"UTD.htm?8/1/8220\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary hypogonadism is characterized by high levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Secondary hypogonadism is characterized by low to normal concentrations of LH and FSH, and typically is caused by impaired secretion of hypothalamic gonadotropin-releasing hormone (GnRH) (",
"      <a class=\"graphic graphic_table graphicRef62372 \" href=\"UTD.htm?1/38/1645\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17171365\">",
"       'Primary versus secondary hypogonadism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No single test reliably distinguishes patients with constitutional delay of puberty (who will eventually progress spontaneously through puberty) from patients with other causes of delayed puberty, particularly congenital GnRH deficiency. The most valuable components of an assessment are a focused history and physical examination, and observation over time. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history helps determine whether pubertal development is totally absent or had started but then \"stalled.\" Patients with constitutional delay of puberty have delayed (not stalled) growth, adrenarche, and sexual development. The history should also solicit information about underlying chronic disease, congenital anomalies, family history of pubertal development, and sense of smell. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination includes accurate determination of Tanner stage of pubertal development, including measurements of height, and weight, and of testicular size in boys. Height velocity should be calculated from serial measurements of height over six months or more. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determination of bone age at the initial evaluation provides valuable information about the relationship between chronologic age and skeletal maturation. Children with constitutional delay of puberty typically have bone ages of 12 to 13.5 years but rarely progress beyond this age without evidence of pubertal maturation. Other imaging studies that are useful in selected patients include pelvic or testicular ultrasound and head magnetic resonance imaging (MRI). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging studies'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Laboratory evaluation for a patient with delayed puberty should include measurement of serum LH and FSH, prolactin, thyroid stimulating hormone (TSH) and free T4. Most patients should also be screened for chronic diseases that may cause pubertal delay, using a complete blood count, erythrocyte sedimentation rate and liver function tests. In selected patients, measurement of adrenal androgens or karyotype is appropriate. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Laboratory testing'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      If a specific underlying disorder can be identified (",
"      <a class=\"graphic graphic_table graphicRef62372 \" href=\"UTD.htm?1/38/1645\">",
"       table 2",
"      </a>",
"      ), therapy should be targeted at that disorder.",
"     </li>",
"     <li>",
"      In most patients, the distinction between congenital GnRH deficiency and constitutional delay of puberty remains uncertain, and can be resolved only with serial observations. Short-term hormonal therapy with testosterone in boys and with estrogen in girls may be appropriate when the pubertal delay is severe or the patient's psychosocial concerns about the delay play a prominent role that cannot be addressed by reassurance and education alone. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/1\">",
"      Sedlmeyer IL, Palmert MR. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab 2002; 87:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/2\">",
"      Caronia LM, Martin C, Welt CK, et al. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med 2011; 364:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/3\">",
"      Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007; 357:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/4\">",
"      Rosenfield RL. Clinical review 6: Diagnosis and management of delayed puberty. J Clin Endocrinol Metab 1990; 70:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/5\">",
"      Kaplowitz PB. Delayed puberty. Pediatr Rev 2010; 31:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/6\">",
"      Boepple PA. Precocious and delayed puberty. Curr Opin Endocrinol Diabetes 1995; 2:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/7\">",
"      Pugliese MT, Lifshitz F, Grad G, et al. Fear of obesity. A cause of short stature and delayed puberty. N Engl J Med 1983; 309:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/8\">",
"      Sedlmeyer IL, Hirschhorn JN, Palmert MR. Pedigree analysis of constitutional delay of growth and maturation: determination of familial aggregation and inheritance patterns. J Clin Endocrinol Metab 2002; 87:5581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/9\">",
"      Waldstreicher J, Seminara SB, Jameson JL, et al. The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. J Clin Endocrinol Metab 1996; 81:4388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/10\">",
"      Balasubramanian R, Dwyer A, Seminara SB, et al. Human GnRH deficiency: a unique disease model to unravel the ontogeny of GnRH neurons. Neuroendocrinology 2010; 92:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/11\">",
"      Gianetti E, Tusset C, Noel SD, et al. TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab 2010; 95:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/12\">",
"      Mitchell AL, Dwyer A, Pitteloud N, Quinton R. Genetic basis and variable phenotypic expression of Kallmann syndrome: towards a unifying theory. Trends Endocrinol Metab 2011; 22:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/13\">",
"      Balasubramanian R, Crowley WF Jr. Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network. Mol Cell Endocrinol 2011; 346:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/14\">",
"      Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/15\">",
"      Marshall JC, Kelch RP. Low dose pulsatile gonadotropin-releasing hormone in anorexia nervosa: a model of human pubertal development. J Clin Endocrinol Metab 1979; 49:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/16\">",
"      Wu FC, Butler GE, Kelnar CJ, et al. Ontogeny of pulsatile gonadotropin releasing hormone secretion from midchildhood, through puberty, to adulthood in the human male: a study using deconvolution analysis and an ultrasensitive immunofluorometric assay. J Clin Endocrinol Metab 1996; 81:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/17\">",
"      Kelch RP, Hopwood NJ, Marshall JC. Diagnosis of gonadotropin deficiency in adolescents: limited usefulness of a standard gonadotropin-releasing hormone test in obese boys. J Pediatr 1980; 97:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/18\">",
"      Savage MO, Preece MA, Cameron N, et al. Gonadotrophin response to LH-RH in boys with delayed growth and adolescence. Arch Dis Child 1981; 56:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/19\">",
"      Harman SM, Tsitouras PD, Costa PT, et al. Evaluation of pituitary gonadotropic function in men: value of luteinizing hormone-releasing hormone response versus basal luteinizing hormone level for discrimination of diagnosis. J Clin Endocrinol Metab 1982; 54:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/20\">",
"      Wilson DA, Hofman PL, Miles HL, et al. Evaluation of the buserelin stimulation test in diagnosing gonadotropin deficiency in males with delayed puberty. J Pediatr 2006; 148:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/21\">",
"      Ghai K, Cara JF, Rosenfield RL. Gonadotropin releasing hormone agonist (nafarelin) test to differentiate gonadotropin deficiency from constitutionally delayed puberty in teen-age boys--a clinical research center study. J Clin Endocrinol Metab 1995; 80:2980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/22\">",
"      Copeland KC, Paunier L, Sizonenko PC. The secretion of adrenal androgens and growth patterns of patients with hypogonadotropic hypogonadism and isiopathic delayed puberty. J Pediatr 1977; 91:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/23\">",
"      Brook CG. Management of delayed puberty. Br Med J (Clin Res Ed) 1985; 290:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/24\">",
"      Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med 1988; 319:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/25\">",
"      Soliman AT, Khadir MM, Asfour M. Testosterone treatment in adolescent boys with constitutional delay of growth and development. Metabolism 1995; 44:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/26\">",
"      Wilson DM, Kei J, Hintz RL, Rosenfeld RG. Effects of testosterone therapy for pubertal delay. Am J Dis Child 1988; 142:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/27\">",
"      Butler GE, Sellar RE, Walker RF, et al. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab 1992; 75:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/28\">",
"      Adan L, Souberbielle JC, Brauner R. Management of the short stature due to pubertal delay in boys. J Clin Endocrinol Metab 1994; 78:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/29\">",
"      Albanese A, Kewley GD, Long A, et al. Oral treatment for constitutional delay of growth and puberty in boys: a randomised trial of an anabolic steroid or testosterone undecanoate. Arch Dis Child 1994; 71:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/30\">",
"      B&uuml;y&uuml;kgebiz A. Treatment of constitutional delayed puberty with a combination of testosterone esters. Horm Res 1995; 44 Suppl 3:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/31\">",
"      Bergad&aacute; I, Bergad&aacute; C. Long term treatment with low dose testosterone in constitutional delay of growth and puberty: effect on bone age maturation and pubertal progression. J Pediatr Endocrinol Metab 1995; 8:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/32\">",
"      Albanese A, Stanhope R. Predictive factors in the determination of final height in boys with constitutional delay of growth and puberty. J Pediatr 1995; 126:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/33\">",
"      Arrigo T, Cisternino M, Luca De F, et al. Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty. J Pediatr Endocrinol Metab 1996; 9:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22424/abstract/34\">",
"      Raivio T, Dunkel L, Wickman S, J&auml;nne OA. Serum androgen bioactivity in adolescence: a longitudinal study of boys with constitutional delay of puberty. J Clin Endocrinol Metab 2004; 89:1188.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5814 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-201.248.109.99-36184B143A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22424=[""].join("\n");
var outline_f21_57_22424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17171410\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17171365\">",
"      PRIMARY VERSUS SECONDARY HYPOGONADISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21033740\">",
"      - General evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21033733\">",
"      - Hormonal tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22059968\">",
"      - Additional tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4873651\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Testosterone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Growth hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17171410\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5814|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/39/17023\" title=\"figure 1\">",
"      Growth puberty chart in boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/46/44781\" title=\"figure 2\">",
"      Testicular volume and sexual maturity rating",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5814|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/1/8220\" title=\"table 1\">",
"      Sexual maturity rating of secondary sexual characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/38/1645\" title=\"table 2\">",
"      Causes of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/55/28540\" title=\"table 3\">",
"      Turner estrogen dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=related_link\">",
"      Induction of fertility in men with secondary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=related_link\">",
"      Management of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=related_link\">",
"      Patient information: Late puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_57_22425="Multiple atypical nevi";
var content_f21_57_22425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78891%7EDERM%2F83351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78891%7EDERM%2F83351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple atypical nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple atypical nevi on the posterior trunk of an adolescent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Clinically atypical nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22425=[""].join("\n");
var outline_f21_57_22425=null;
var title_f21_57_22426="Restoration of sinus rhythm in atrial fibrillation";
var content_f21_57_22426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Restoration of sinus rhythm in atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Gerald Naccarelli, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22426/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/57/22426/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/57/22426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8701623\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The restoration of sinus rhythm (SR) is performed in many patients with atrial fibrillation (AF) to improve symptoms. This topic will focus on the efficacy and safety of the two most widely used approaches for converting AF to SR: direct current (DC) and pharmacologic cardioversion. The discussion of the maintenance of SR in patients with AF is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952132725\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The restoration of sinus rhythm (SR) is often performed in the following settings to improve cardiovascular outcomes or symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unstable hemodynamics",
"     </li>",
"     <li>",
"      First episode, irrespective of whether a long-term strategy of either rhythm or rate control is chosen (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H8#H8\">",
"       \"Rhythm control versus rate control in atrial fibrillation\", section on 'Comparative studies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H5421057#H5421057\">",
"       \"Rhythm control versus rate control in atrial fibrillation\", section on 'Summary and recommendations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infrequent episodes that do not convert spontaneously",
"     </li>",
"     <li>",
"      Worsening symptoms ascribed to atrial fibrillation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412568\">",
"    <span class=\"h2\">",
"     Unstable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency direct current (DC) cardioversion should be performed if the patient is compromised hemodynamically due to a rapid ventricular rate or, perhaps, the lack of atrial contribution to cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This includes patients with severe acute left heart failure, ongoing myocardial ischemia, or hypotension. However, if hypotension occurs with a slow or moderate ventricular response (&lt;130",
"    <span class=\"nowrap\">",
"     beats/min),",
"    </span>",
"    other causes of hypotension should be sought, such as myocardial infarction, pulmonary embolism, sepsis, or hypovolemia. In most patients, there is time to attempt rate slowing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link&amp;anchor=H2#H2\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Adverse hemodynamics in AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412561\">",
"    <span class=\"h2\">",
"     Stable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stable patients with AF who are candidates for cardioversion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with new onset or newly recognized AF are candidates for cardioversion. We believe that most such patients who are symptomatic should have at least one cardioversion attempt, as the likelihood of success will be high and the natural history of the disease may be such that sinus rhythm will be maintained for a relatively long period. However, this recommendation may not apply to the elderly (&gt;80 years) with multiple comorbidities, where risks of undergoing cardioversion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pharmacologic rhythm control may outweigh the benefits of restoring sinus rhythm. These issues are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of new onset atrial fibrillation\", section on 'Cardioversion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with persistent AF who are limited symptomatically by the AF. Occasionally, it may be appropriate to attempt to restore SR in a patient with longstanding or even permanent AF. An example of the latter is a patient with AF of long duration who now has developed increasing heart failure or tachycardia-induced cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"       \"Atrial fibrillation in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"       \"Tachycardia-mediated cardiomyopathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Frequently, the only way to determine if subtle, nonspecific symptoms are attributable to AF is to restore SR to see if symptoms improved. Given mechanical recovery of atrial mechanical function is related to the duration of AF prior to cardioversion, it may take several weeks for full mechanical benefit of SR to be manifest.",
"     </li>",
"     <li>",
"      Patients with infrequent symptomatic episodes of AF may be candidates for periodic cardioversion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"       \"Rhythm control versus rate control in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest that AF patients with either evidence of ventricular preexcitation or individuals taking a class I or class II antiarrhythmic drug who are candidates for cardioversion be managed by an expert in rhythm disorders. The risk of complications at the time of cardioversion is increased in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link\">",
"     \"Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166080599\">",
"    <span class=\"h2\">",
"     Reasons to not cardiovert",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumstances in which it is reasonable to avoid cardioversion attempts in patients with new onset AF include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are minimally symptomatic, particularly those with multiple comorbidities or poor overall prognosis, where the risks of undergoing cardioversion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pharmacologic rhythm control may outweigh the benefits of restoring sinus rhythm. There is no age cut-off for the restoration of sinus rhythm, but the benefit from cardioversion begins to decline as age increases after 80.Patients with a low likelihood of maintenance of sustained SR (see below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with paroxysmal AF are usually not cardioverted, as the AF is often of short duration, resolves spontaneously, and almost always. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of atrial fibrillation\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following factors decrease the likelihood of success of immediate conversion as well as long-term maintenance of SR; they should be considered when deciding whether to perform a cardioversion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AF has been present continuously for more than one year [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/1-8\">",
"       1-8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The left atrium is markedly enlarged (atrial dimension &gt;5.0 cm) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/9-13\">",
"       9-13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elderly (&gt;80 years of age) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Associated cardiovascular conditions (eg, left ventricular dysfunction) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients who had recurrence while taking adequate doses of appropriate antiarrhythmic drug therapy. Drug refractory patients may be able to be converted to SR but are less likely to maintain SR long term.",
"     </li>",
"     <li>",
"      Cardioversion with maintenance of SR is likely to be unsuccessful if the cause (thyrotoxicosis, pericarditis, and mitral stenosis) for the AF has not been corrected prior to attempted cardioversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102941455\">",
"    <span class=\"h1\">",
"     DECISIONS BEFORE CARDIOVERSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701631\">",
"    <span class=\"h2\">",
"     Ventricular rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically stable patients with a rapid ventricular response usually need acute control of their ventricular rate to improve symptoms. In stable patients, this can be achieved by oral (and occasionally intravenous) administration of beta blockers or nondihydropyridine calcium channel antagonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In the acute setting, the target ventricular rate should usually be 80 to 100 beats per minute.",
"   </p>",
"   <p>",
"    In patients with severe left ventricular systolic dysfunction and heart failure, calcium channel blockers are contraindicated, and the use of beta blockers may not be appropriate in a decompensated patient. In this setting, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After ventricular rate control has been achieved, many patients will convert to SR spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Spontaneous conversion is most likely to occur in patients with a duration of AF less than 48 hours, or in patients who give a history of short self-limited episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The rate of spontaneous conversion has been reported to be around 50 percent at 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701646\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an AF duration longer than 48 hours or of unknown duration should be anticoagulated prior to cardioversion. Anticoagulation should also be considered for some patients if the duration is less than 48 hours. Issues related to anticoagulation in patients for whom the restoration of SR is being considered are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413218\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of cardioversion (except in patients who are unstable) is determined in large measure by the duration of the episode. For non-valvular AF, there is a very low risk of systemic embolization if the duration of the arrhythmia is less than 48 hours",
"    <strong>",
"     and",
"    </strong>",
"    there are no cardiac abnormalities (significant left ventricular enlargement due to a cardiomyopathy) on transthoracic echocardiography, and no prior history of thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/18\">",
"     18",
"    </a>",
"    ]. Most patients with new onset AF of longer than 48 hours or of unknown duration should be anticoagulated before cardioversion (",
"    <a class=\"graphic graphic_algorithm graphicRef65399 \" href=\"UTD.htm?34/37/35423\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8701646\">",
"     'Anticoagulation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H526865111#H526865111\">",
"     \"Management of new onset atrial fibrillation\", section on 'Early cardioversion or spontaneous reversion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is useful to evaluate the patient for an underlying or precipitating cause, such as hyperthyroidism, prior to performing cardioversion. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of new onset atrial fibrillation\", section on 'Evaluation for an underlying cause'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413338\">",
"    <span class=\"h1\">",
"     DC VERSUS PHARMACOLOGIC CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer direct current (DC) to pharmacologic cardioversion for most patients. (See",
"    <a class=\"local\" href=\"#H8701669\">",
"     'Pretreatment with antiarrhythmic drugs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H166080599\">",
"     'Reasons to not cardiovert'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The two strategies for cardioversion have not been compared to each other in carefully controlled trials. Evidence from studies that compare antiarrhythmic agents to placebo suggests significantly lower rates of successful conversion using drugs as compared to DC cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link&amp;anchor=H17047227#H17047227\">",
"     \"Clinical uses of amiodarone\", section on 'Oral amiodarone for pharmacologic cardioversion of atrial fibrillation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link&amp;anchor=H10#H10\">",
"     \"Therapeutic use of dofetilide\", section on 'Oral dofetilide for atrial arrhythmia termination and prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=see_link&amp;anchor=H5117190#H5117190\">",
"     \"Therapeutic use of ibutilide\", section on 'Atrial fibrillation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8701769\">",
"     'Flecainide'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8701654\">",
"     'DC cardioversion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to a lower success rate, other disadvantages of pharmacologic cardioversion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The needs for telemetric monitoring for a period of time (perhaps as long as 50 percent of the drug&rsquo;s elimination half-life) to screen for a proarrhythmic response [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/2\">",
"       2",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      AF may convert to atrial flutter. The class IA drugs (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 1",
"      </a>",
"      ) may both slow the rate of the atrial flutter through their direct effects on sodium channels and enhance atrioventricular (AV) nodal conduction through their vagolytic effect. The net result may be an increased AV conduction at ventricular rates that may exceed 220 to 250",
"      <span class=\"nowrap\">",
"       beats/min.",
"      </span>",
"      Class IC drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ) do not have a vagolytic effect, but can slow the rate of atrial flutter sufficiently to permit rapid one-to-one AV conduction. In the hemodynamically stable patient, the ventricular rate should usually be controlled with an AV nodal blocking drug, as discussed above, before a class IA or IC drug is given. (See",
"      <a class=\"local\" href=\"#H8701631\">",
"       'Ventricular rate control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other reasons to initiate pharmacologic therapy prior to cardioversion are discussed below. (See",
"    <a class=\"local\" href=\"#H8701669\">",
"     'Pretreatment with antiarrhythmic drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414573\">",
"    <span class=\"h2\">",
"     Choice of cardioversion method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the advantages and disadvantages of each method, which are discussed below, our preferences are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emergency DC cardioversion is recommended if the patient is hemodynamically compromised due to a rapid ventricular rate or, perhaps, the lack of atrial contribution to cardiac output. (See",
"      <a class=\"local\" href=\"#H412568\">",
"       'Unstable patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DC cardioversion for well-compensated patients with a first episode (or",
"      <span class=\"nowrap\">",
"       rare/intermittent",
"      </span>",
"      episodes) of AF, who have no or minimal structural heart disease.",
"     </li>",
"     <li>",
"      We start with an antiarrhythmic drug in patients with long-standing AF (often associated with modest left atrial dilation) in whom long-term maintenance drug therapy is anticipated (rhythm control strategy). DC cardioversion is then performed if drug therapy has failed to convert the patient.",
"      <br/>",
"      <br/>",
"      Pharmacologic conversion is preferred in those for whom the risk of procedural sedation is high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701654\">",
"    <span class=\"h1\">",
"     DC CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;DC cardioversion is often performed without the concomitant use of antiarrhythmic drugs. This is particularly true for unstable patients who need immediate restoration of SR. Pretreatment with antiarrhythmic drugs may also be omitted in patients with new onset AF or those in whom the potential for drug induced arrhythmias are a concern. (See",
"    <a class=\"local\" href=\"#H8701669\">",
"     'Pretreatment with antiarrhythmic drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The overall immediate success rate of DC cardioversion is significantly much higher with the more recently developed biphasic, as compared to the older monophasic, shock (94 compared with 84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/7-12,19,20\">",
"     7-12,19,20",
"    </a>",
"    ]. The overall success rate falls as the duration in AF increases. These immediate success rates are higher than the maintenance of SR over time since many patients have immediate or early recurrence of their AF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701669\">",
"    <span class=\"h2\">",
"     Pretreatment with antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs may be initiated prior to electrical cardioversion to increase the likelihood of successful cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/4\">",
"     4",
"    </a>",
"    ] including long-term maintenance of SR. The decision to pretreat is often made by a physician experienced with the care of patients with one or more risk factors for cardioversion failure. (See",
"    <a class=\"local\" href=\"#H166080599\">",
"     'Reasons to not cardiovert'",
"    </a>",
"    above.) As mentioned above, the antiarrhythmic drug will restore SR prior to DC cardioversion in some cases. (See",
"    <a class=\"local\" href=\"#H413338\">",
"     'DC versus pharmacologic cardioversion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another reason to consider starting an antiarrhythmic drug before cardioversion is that it might help prevent recurrent episodes of AF very soon after cardioversion. There is a condition known as early return of AF.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    may be useful in preventing early recurrences of AF after cardioversion, particularly if it is of recent onset [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Ibutilide is used by some of our authors, for instance, in patients with immediate or early recurrence of AF after cardioversion.",
"   </p>",
"   <p>",
"    A third reason to consider pretreatment with antiarrhythmic drugs prior to DC cardioversion is that for patients in whom long-term antiarrhythmic therapy will be used, pre-cardioversion initiation may allow for an evaluation of tolerability of one or more drugs. For those patients in whom a decision has been made to attempt the long-term maintenance of SR with antiarrhythmic drug therapy, we believe it is reasonable to preferentially select a drug for cardioversion that can also be used for long-term maintenance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701684\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detailed discussion of DC cardioversion is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are a few basic points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should be fasting for six to eight hours, oxygen saturation and electrolytes should be close to normal (particularly serum potassium), anticoagulation status should be reviewed (anticoagulation status is crucial to prevent risk for stroke and the need for and the type of anticoagulation depends on the patient&rsquo;s clinical presentation as discussed elsewhere), and drug levels, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      and antiarrhythmic drugs as necessary and as measurable, should be within the therapeutic range. Digoxin need not be withheld unless digitalis toxicity is suspected [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"       \"Digitalis (cardiac glycoside) poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Synchronized DC cardioversion should be performed while the patient is under the influence of procedural sedation and is having the blood pressure, heart rate, and oxygen saturation, CO2 capnography monitored. Generally, cardioversion should be done in a situation where airway equipment and airway expertise are present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"       \"Procedural sedation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DC cardioversion is associated with complications such respiratory distress, myocardial necrosis, skin burns, transient ventricular dysfunction, and transient arrhythmias including bradycardia. These are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link&amp;anchor=H2560757#H2560757\">",
"       \"Cardioversion for specific arrhythmias\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701706\">",
"    <span class=\"h2\">",
"     Hemodynamic changes after reversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular systolic function often improves and may normalize after reversion of AF. In one study, left ventricular function improved soon after the restoration of SR, a change that was attributed to the reduction in heart rate and return of atrial mechanical contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with a relatively small left atrium show evidence of atrial systole early after cardioversion, while atrial contractility improves more slowly when the left atrium is enlarged due to atrial \"stunning,\" and when the duration of AF prior to cardioversion is prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/25\">",
"     25",
"    </a>",
"    ]. In uncommon instances, there can be ventricular \"stunning.\" In these rare cases, there can be acute pulmonary edema after cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43528?source=see_link&amp;anchor=H4#H4\">",
"     \"Mechanisms of thrombogenesis in atrial fibrillation\", section on 'Atrial stunning after cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701722\">",
"    <span class=\"h2\">",
"     Recurrence of AF after cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although DC cardioversion is an effective technique for restoring SR, the recurrence rate is high, particularly without maintenance antiarrhythmic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/26\">",
"     26",
"    </a>",
"    ]. The timing of AF recurrence was evaluated in a review of 61 patients who had daily electrocardiographic recordings using trans-telephonic monitoring: 57 percent had recurrent AF during the first month after cardioversion, with a peak incidence during the first five days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DC cardioversion may be repeated if AF recurs acutely in patients who have not been pretreated with antiarrhythmic therapy. In such patients or those in whom cardioversion fails, the combination of an AV nodal blocker plus intravenous loading with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    may pharmacologically restore SR. If the AF persists, DC cardioversion is performed and, if successful, the patient may be placed on long-term antiarrhythmic therapy. (See",
"    <a class=\"local\" href=\"#H8701755\">",
"     'Antiarrhythmic drugs used in cardioversion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A separate issue is whether to perform repeat cardioversion for later recurrence. Less than 14 percent of patients remain in SR for a prolonged period after a third cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/28\">",
"     28",
"    </a>",
"    ]. However, an important consideration is the duration between AF episodes. In both of the above reports, a third cardioversion for recurrent AF was performed within seven days of the second cardioversion. Repeated cardioversion may be a reasonable approach for patients with AF that recurs after a longer duration of SR. It is most likely to be successful in younger patients with fair exercise tolerance and AF duration of less than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/29\">",
"     29",
"    </a>",
"    ]. Repeat cardioversion or nonpharmacologic therapy (catheter ablation of AF) may be necessary in patients who remain symptomatic when in recurrent AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952133140\">",
"    <span class=\"h3\">",
"     Maintenance antiarrhythmic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After successful DC cardioversion has been performed, antiarrhythmic drugs increase the likelihood of maintenance of SR [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/4\">",
"     4",
"    </a>",
"    ]. The use of antiarrhythmic agents to maintain SR is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not generally recommend maintenance antiarrhythmic drugs after DC cardioversion in patients with their",
"    <strong>",
"     first",
"    </strong>",
"    episode of AF, particularly those at low risk for recurrence (eg, short duration and normal left atrial size) or those with a transient cause (such as cardiac surgery, pericarditis, pulmonary embolism, and corrected or treated hyperthyroidism) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701755\">",
"    <span class=\"h1\">",
"     ANTIARRHYTHMIC DRUGS USED IN CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above some patients have antiarrhythmic drugs started before DC cardioversion (",
"    <a class=\"graphic graphic_table graphicRef74104 \" href=\"UTD.htm?19/11/19645\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8701669\">",
"     'Pretreatment with antiarrhythmic drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    On rare occasions, cardioversion with an antiarrhythmic drug can be appropriate, such as those for whom the risk of anesthesia is high. &nbsp;",
"   </p>",
"   <p>",
"    Various guidelines include recommendations for the choice of antiarrhythmic drug, which vary with the duration of AF and the presence or absence of structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. We agree with these guidelines, which concluded that if the duration of AF is a week or less,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    (to treat persistent AF with the possible effect of cardioversion as well),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , or, to a lesser degree,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    have efficacy for medical conversion of AF. If the AF is greater than seven days&rsquo; duration, dofetilide or, to a lesser degree, amiodarone or ibutilide have some role for medical conversion of persistent AF. However, in almost all circumstances, pharmacologic cardioversion is not the primary choice to convert patients to sinus rhythm.",
"   </p>",
"   <p>",
"    Structural heart disease is a contraindication to the use of some of the antiarrhythmic drugs discussed below. We define it as any condition in which there is a deviation in the size, shape, function, or structure of the atria or ventricles (such as left ventricular hypertrophy or dilated cardiomyopathy) or of the heart valves. This also includes any abnormalities in the coronary arteries. The definition does not include processes that alter the electrical properties of the heart, such as electrical activation, conduction, automaticity, or refractoriness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701769\">",
"    <span class=\"h2\">",
"     Flecainide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    , a class IC drug (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ), is a very effective antiarrhythmic drug for the conversion of patient with AF of short (&lt;24 hours) duration (",
"    <a class=\"graphic graphic_table graphicRef74104 \" href=\"UTD.htm?19/11/19645\">",
"     table 2",
"    </a>",
"    ). Flecainide should not be used in patients with structural heart disease, particularly those with reduced left ventricular systolic dysfunction and in those with ischemic coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"     \"Major side effects of class I antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 10 min) acutely reverts recent onset AF in 67 to 92 percent of patients within six hours and is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . The intravenous preparation is not available in the United States. An oral dose of 200 to 300 mg has also been used.",
"   </p>",
"   <p>",
"    A single, large oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    (100 to 400 mg) is effective for AF reversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. One study randomly assigned 79 patients to intravenous or large oral dose of flecainide. The rate of reversion to SR was similar at two hours (64 versus 68 percent for oral drug) and eight hours after treatment (72 versus 75 percent); however, the mean time to reversion was shorter with intravenous drug (52 versus 110 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/32\">",
"     32",
"    </a>",
"    ]. This oral &ldquo;pill-in-the-pocket&rdquo; approach is mainly to facilitate conversion of what may be recent onset and paroxysmal episodes of AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701777\">",
"    <span class=\"h2\">",
"     Propafenone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 10 to 20 min) is used in Europe for the acute termination of AF (",
"    <a class=\"graphic graphic_table graphicRef74104 \" href=\"UTD.htm?19/11/19645\">",
"     table 2",
"    </a>",
"    ). Conversion rates of 23 to 54 percent in patients with AF of variable duration have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     Propafenone",
"    </a>",
"    is significantly more effective in paroxysmal as opposed to persistent AF, with rates likely approaching those seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/2\">",
"     2",
"    </a>",
"    ]. We suggest not using propafenone in patients with structural heart disease, particularly those with reduced left ventricular systolic dysfunction, and those with ischemic coronary artery disease.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    can be given as a large dose of 450 to 600 mg. A single oral loading dose reverted AF in 56 to 83 percent of patients, depending upon the duration of AF, in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The administration of propafenone prior to electrical cardioversion does not alter the energy requirements for or the success rate of cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701784\">",
"    <span class=\"h2\">",
"     Ibutilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    is available only as an intravenous preparation (1 mg over 10 minutes and potentially repeated once after 20 minutes) and is useful for the acute reversion of AF (",
"    <a class=\"graphic graphic_table graphicRef74104 \" href=\"UTD.htm?19/11/19645\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. It has been used in patients with structural heart disease (but without heart failure). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=see_link\">",
"     \"Therapeutic use of ibutilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In trials, the acute AF conversion rate is 28 to 31 percent.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    can work in acute situations of persistent AF and can be used (with caution) in patients with structural heart disease. However, it should be pointed out that, while these rates seem low compared to those with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , these drugs have never been directly compared. In addition, the average conversion times with ibutilide seem shorter than with the other two drugs.",
"   </p>",
"   <p>",
"    Arrhythmia conversion occurred within a mean of 27 to 33 minutes after the start of the infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In comparative studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    has been more effective for AF reversion than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    (51 versus 21 percent and 32 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (44 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    is a class III antiarrhythmic drug (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) that prolongs repolarization and the QT interval. It has the potential to provoke torsade de pointes, similar to other agents in this class. In four large series, the rate of torsade de pointes ranged between 3.6 and 8.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/38-40,42\">",
"     38-40,42",
"    </a>",
"    ]. Sustained episodes of torsade de pointes, requiring cardioversion, were seen in 1.7 to 2.4 percent. In addition to polymorphic VT, nonsustained monomorphic VT occurred in an additional 3.2 to 3.6 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Because of the risk of ventricular proarrhythmia, patients treated with ibutilide should be observed with continuous ECG monitoring for at least four hours after the infusion or until the QTc interval has returned to baseline. Pretreatment with intravenous magnesium appears to minimize the risk of ibutilide induced torsade de pointes without affecting the efficacy of conversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/44\">",
"     44",
"    </a>",
"    ]. Risk factors for the development of torsade de pointes with ibutilide are heart failure, baseline increase in QTc interval, and low potassium or magnesium.",
"   </p>",
"   <p>",
"    Although pretreatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    has been shown to improve the efficacy of DC cardioversion (and can prevent immediate recurrences) and lower the cardioversion energy requirement, the use of biphasic shock waveforms has all but eliminated the practice of using IV ibutilide or other drugs to lower the cardioversion energy requirement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/45\">",
"     45",
"    </a>",
"    ]. It has been used in patients resistant to DC cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H13#H13\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended dose varies with patient size. For patients weighing less than 60 kg, the recommended dose is 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infused over 10 minutes. If the arrhythmia does not terminate 10 minutes after the end of the infusion, a second bolus (same dose over 10 minutes) can be given. For patients weighing more than 60 kg, the recommended starting intravenous dose is 1 mg over 10 minutes. If AF does not terminate 10 minutes after the end of the infusion, a second bolus of 1 mg over 10 minutes can be given. Most patients studied have had arrhythmia for less than 90 days. Efficacy has not been proven with arrhythmia duration exceeding 90 days.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    is used occasionally by our experts in patients resistant to DC cardioversion and in patients for whom anesthesia, in conjunction with DC cardioversion, is not readily available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701791\">",
"    <span class=\"h2\">",
"     Dofetilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cardioversion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    is less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , and possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , but more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . It should be pointed out that dofetilide has not been directly compared to amiodarone or vernakalant. Its principle use is to help maintain sinus rhythm, rather than to be used for cardioversion.",
"   </p>",
"   <p>",
"    It has the disadvantage of requiring the patient to be hospitalized. It has been used successfully in patients with structural heart disease. As an oral agent, it is rarely used solely for the purpose of cardioversion. It can be started prior to anticipated DC cardioversion to help maintain sinus rhythm shortly after either DC or spontaneous cardioversion, or in those patients in whom it is chosen for the long-term maintenance of sinus rhythm.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    is a class III antiarrhythmic drug (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) and I",
"    <sub>",
"     Kr",
"    </sub>",
"    blocker that is available in the United States, but not Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    is more effective than placebo for the conversion of persistent AF to SR, particularly at a dose of 500 &micro;g twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. As an example, the SAFIRE-D study randomized 325 patients with AF (n = 277) or atrial flutter (n = 48) to oral therapy with 125, 250, and 500 &micro;g twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/47\">",
"     47",
"    </a>",
"    ]. In this study, about 60 percent of patients had structural heart disease. Overall conversion rates were 6, 9.8, and 30 percent, respectively. Among patients who convert with dofetilide, conversion to SR occurred in 70 percent within 24 hours, while 91 percent converted to SR within 36 hours. Postmarket uncontrolled trials have suggested that oral dofetilide is useful in the medical conversion of persistent AF in up to 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with other class III drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    can cause nonsustained ventricular tachycardia, torsade de pointes, or sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/46\">",
"     46",
"    </a>",
"    ]. In the SAFIRE-D trial the incidence of torsade was 1.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/47\">",
"     47",
"    </a>",
"    ]. This risk is minimized by dosing based on the creatinine clearance and avoidance of other drugs that may cause torsade de pointes. Initiation of dofetilide is required to be in-hospital, under telemetry conditions by a doctor certified in its use with a total of at least six dosages given before discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701799\">",
"    <span class=\"h2\">",
"     Amiodarone (intravenous)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is not particularly effective and occurs several hours later than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    and vernakalant (",
"    <a class=\"graphic graphic_table graphicRef74104 \" href=\"UTD.htm?19/11/19645\">",
"     table 2",
"    </a>",
"    ). However, it has been used successfully in patients with structural heart disease. We recommend starting intravenous amiodarone prior to cardioversion when it will be used for maintenance therapy. It can also control the ventricular rate. It is occasionally used in patients in whom the success rate of DC cardioversion is anticipated to be low or in whom there is a concern about early relapse after successful DC cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H5304343#H5304343\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over one hour, with a subsequent infusion of 1",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    (for as long as needed) is associated with a low rate of conversion of AF to SR [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. It should be kept in mind that the drug will likely have a significant rate-slowing effect, which may be beneficial in some patients.",
"   </p>",
"   <p>",
"    Reports differ in the conversion rate due to differences in the patient population and in the timing of the endpoint. The following are representative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 100 patients with recent onset AF who were randomly assigned to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or saline, there was no difference in rate of conversion (68 versus 60 percent respectively) at 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The AVRO trial, which randomly assigned 116 patients with recent onset AF to IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or vernakalant, the rates of conversion were 5.2 and 52 percent respectively at 90 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 150 symptomatic patients with acute AF who were randomly assigned to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , the rates of conversion at 12 hours were 90, 72, and 64 percent respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a meta-analysis of 595 patients, there was no significant effect on conversion up to two hours, but significant effects at six to eight (RR 1.23) and 24 hours (RR 1.44). Efficacy was significantly less compared to class IC oral drugs at six to eight hours (RR 0.67), but not at 24 hours (RR 0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/55\">",
"     55",
"    </a>",
"    ]. Although the results for converting AF are mixed at best, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is very effective in controlling the ventricular rate response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701807\">",
"    <span class=\"h2\">",
"     Amiodarone (oral)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is not as effective as class IA or IC drugs for reverting AF. Although commonly used, amiodarone (either oral or intravenous) is not approved by the United States Food and Drug Administration for the treatment of AF.",
"   </p>",
"   <p>",
"    A number of mostly small trials have evaluated the efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    for cardioversion; as with other antiarrhythmic drugs, this varies with the duration of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. In two studies of patients with recent onset AF, the rates of conversion with oral amiodarone at 24 hours were 47 and 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/57,61\">",
"     57,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was best studied in the SAFE-T trial of 665 patients with persistent AF (at least 72 hours, but 20 percent had AF for more than one year). The patients were randomly assigned to amiodarone (800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first 14 days, 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the next 14 days, and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for first year),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (80 mg twice daily for the first week and 160 mg twice daily thereafter), or placebo. With respect to the frequency of cardioversion to SR at 28 days, amiodarone and sotalol were equally effective and more effective than placebo (27.7 and 26.5 versus 0.8 percent, respectively). Patients who were still in AF at 28 days underwent DC cardioversion. The efficacy of cardioversion was similar in the three groups (72.3, 73.5, and 67.9 percent, respectively). Thus, SAFE-T did not confirm a previous suggestion in a much smaller randomized trial that amiodarone increases the efficacy of DC cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701815\">",
"    <span class=\"h2\">",
"     Vernakalant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous vernakalant is approved by the European Commission for the rapid conversion of recent-onset AF (&le;7 days&rsquo; duration for patients not undergoing surgery, and &le;3 day&rsquo;s duration for postcardiac surgery patients) to SR (",
"    <a class=\"graphic graphic_table graphicRef74104 \" href=\"UTD.htm?19/11/19645\">",
"     table 2",
"    </a>",
"    ). This drug is not available in the United States.",
"   </p>",
"   <p>",
"    Vernakalant blocks sodium and potassium currents, including the atrial-selective currents I",
"    <sub>",
"     Kur",
"    </sub>",
"    and I",
"    <sub>",
"     K,ACh",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/62\">",
"     62",
"    </a>",
"    ]. Vernakalant significantly prolongs the atrial refractory period with minimal effects on ventricular refractoriness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link&amp;anchor=H10#H10\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\", section on 'Class III'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of vernakalant for the restoration of SR has been evaluated in four randomized trials in which there was a 10-minute intravenous infusion at a dose of 3 mg per kg followed by a second 10-minute infusion at a dose of 2 mg per kg 15 minutes later if AF had not been terminated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ACT I and ACT III trials investigated vernakalant in the treatment of patients with sustained AF (duration greater than three hours, but not more than 45 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. The primary endpoint in both trials was the proportion of patients with short-duration AF (three hours to seven days) who had treatment-induced conversion of AF to SR for at least 1 minute within 90 minutes of treatment infusion. The primary endpoint was met in approximately 51.0 percent of patients receiving vernakalant both studies. Conversion of AF to SR occurred rapidly, with a median time to conversion in responders of 10.",
"     </li>",
"     <li>",
"      In the AVRO trial, intravenous vernakalant versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (administered over two hours) was compared in 116 patients with recent-onset AF (3 to 48 hours). By 90 minutes, vernakalant converted 52 percent of patients with AF to SR compared to only 5.2 percent of patients treated with amiodarone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/53\">",
"       53",
"      </a>",
"      ]. Serious adverse events with vernakalant were uncommon.",
"     </li>",
"     <li>",
"      The ACT II trial investigated the effect of vernakalant in 150 patients with sustained AF (3 to 72 hours duration) that occurred between 24 hours and seven days after coronary artery bypass graft",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      valvular surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/60\">",
"       60",
"      </a>",
"      ]. The primary endpoint was the conversion to SR within 90 minutes of dosing, which was achieved in 47 out of 100 (47 percent) patients who received vernakalant compared with 7 out of 50 (14 percent) patients who received placebo.",
"     </li>",
"     <li>",
"      The safety of this drug remains uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701822\">",
"    <span class=\"h2\">",
"     Less effective drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several older medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    had been used clinically for many years; however, because other agents have greater efficacy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fewer side effects, these medications are no longer recommended. The following is a limited review of other therapies that have minimal efficacy for the conversion of AF to SR. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701836\">",
"    <span class=\"h3\">",
"     Sotalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    is less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/64\">",
"     64",
"    </a>",
"    ] and equally effective to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    for chemical cardioversion (27 percent at 28 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/55\">",
"     55",
"    </a>",
"    ]. Intravenous sotalol, is less effective than intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    for reversion of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/43,65\">",
"     43,65",
"    </a>",
"    ]. Thus, we don&rsquo;t recommend either form for chemical cardioversion of AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701843\">",
"    <span class=\"h3\">",
"     Dronedarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    for the restoration of SR in patients with AF. The discussion of the role of dronedarone for the maintenance of SR in patients with AF is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8701851\">",
"    <span class=\"h2\">",
"     Ineffective drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rate-control drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , calcium channel blockers and beta blockers are not appropriate for the pharmacologic cardioversion of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/4,66-71\">",
"     4,66-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872637949\">",
"    <span class=\"h1\">",
"     SICK SINUS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sinus or atrioventricular (AV) node dysfunction, as in the bradycardia-tachycardia syndrome, are at higher risk for significant sinus pauses and bradycardia if their AF is converted without a back-up pacemaker. Nevertheless, the hemodynamic benefit from cardioversion may be sufficient to warrant restoration of SR with control of the atrial rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atrioventricular conduction with a pacemaker. Physiologic pacing in patients with sick sinus syndrome and SR appears to decrease the likelihood of developing AF, especially if the initiation of AF episodes is bradycardia-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952133456\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 European Society of Cardiology guidelines on the management of AF make the following recommendations for patients with recent onset (&lt;48 hours) AF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When pharmacologic therapy is preferred to electrical cardioversion:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For those without structural heart disease, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      (not available in the United States) is preferred for cardioversion (strong recommendation). Also, a single, high oral dose of flecainide or propafenone may be considered (weak recommendation).",
"     </li>",
"     <li>",
"      For those with structural heart disease, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is preferred (strong recommendation).",
"     </li>",
"     <li>",
"      In patients with structural heart disease, but without hypotension or manifest heart failure,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      may be considered (weak recommendation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DC cardioversion is the primary conversion strategy; pretreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      should be considered to enhance success and prevent recurrent AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology guidelines make similar recommendations and these were not changed in the 2011 update [",
"    <a class=\"abstract\" href=\"UTD.htm?21/57/22426/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to the recommendations above, our experts rarely use pharmacologic therapy for AF cardioversion. As discussed above, antiarrhythmic drugs are used as pretreatment prior to electrical cardioversion in some cases and to facilitate conversion of episodes of the AF that may be paroxysmal in any event. (See",
"    <a class=\"local\" href=\"#H8701669\">",
"     'Pretreatment with antiarrhythmic drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872637764\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are hemodynamically unstable due to atrial fibrillation (AF), we recommend urgent DC cardioversion. In some of these patients, time will allow for a brief trial of rate slowing therapy. (See",
"      <a class=\"local\" href=\"#H412568\">",
"       'Unstable patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For some stable patients with AF, the restoration of sinus rhythm with either direct current (DC) or pharmacologic cardioversion is necessary or reasonable (see",
"      <a class=\"local\" href=\"#H952132725\">",
"       'Candidates for cardioversion'",
"      </a>",
"      above): &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most symptomatic patients with new onset or newly recognized AF, we recommend an attempt at cardioversion, as opposed to no attempt (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In elderly patients or those with multiple medical comorbidities, it is reasonable to not restore sinus rhythm if the symptoms can be minimized.",
"     </li>",
"     <li>",
"      For some patients in whom a long-term strategy with rate control has failed and a rhythm control strategy has been chosen, cardioversion may need to be performed. For example, a patient previously in sinus rhythm with a rate control strategy who has now been in AF for more than 48 hours and in whom a rhythm control strategy has been chosen may need to be cardioverted.",
"     </li>",
"     <li>",
"      Patients with infrequent episodes of AF that do not spontaneously convert, including those being managed with a rhythm control strategy, are candidates for periodic DC cardioversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients in whom cardioversion is chosen will need the ventricular rate controlled and the need for anticoagulation assessed prior to cardioversion. (See",
"      <a class=\"local\" href=\"#H8701631\">",
"       'Ventricular rate control'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8701646\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with new onset AF who do not have factors that predict a lower likelihood of success of DC cardioversion, such as an enlarged left atrium, and in whom long-term maintenance antiarrhythmic drug therapy is not planned, we recommend DC instead of pharmacologic cardioversion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H166080599\">",
"       'Reasons to not cardiovert'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H413338\">",
"       'DC versus pharmacologic cardioversion'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs may be initiated prior to DC cardioversion to increase the likelihood of a successful electrical cardioversion, to increase the likelihood of maintaining sinus rhythm in the hours after cardioversion, or as the first step in a plan for long-term antiarrhythmic therapy. The choice to do so usually occurs in patients with prior efforts at the restoration of sinus rhythm (",
"      <a class=\"graphic graphic_table graphicRef74104 \" href=\"UTD.htm?19/11/19645\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8701669\">",
"       'Pretreatment with antiarrhythmic drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with AF and no structural heart disease for whom pharmacologic cardioversion is chosen, we recommend either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      instead of other antiarrhythmic drugs (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8701755\">",
"       'Antiarrhythmic drugs used in cardioversion'",
"      </a>",
"      above.) Intravenous is preferred to oral therapy when available. The choice between these drugs should be influenced by the practitioner&rsquo;s experience with their use and the clinical situation. Some of our experts are comfortable using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      in this setting.",
"     </li>",
"     <li>",
"      A decision to use antiarrhythmic drug therapy in patients with structural heart disease will likely occur in those for whom long-term antiarrhythmic therapy is being considered. In these patients, the choice of drug will be driven by the agent chosen for maintenance therapy. Drugs that can be used prior to DC cardioversion include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      . The choice of drug should be heavily influenced by a practitioners experience with these agents. For the rare patient with structural heart disease in whom an attempt at pharmacologic cardioversion (with electrical cardioversion) will be made, the same comments apply. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H5304343#H5304343\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients, especially those with AF duration longer than 48 hours or of unknown duration, should be anticoagulated prior to cardioversion. Issues related to anticoagulation in patients for whom the restoration of SR is being considered are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H5304343#H5304343\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/2\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/3\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/4\">",
"      Naccarelli GV, Dell'Orfano JT, Wolbrette DL, et al. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol 2000; 85:36D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/5\">",
"      Falk RH. Atrial fibrillation. N Engl J Med 2001; 344:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/6\">",
"      Resnekov L, McDonald L. Appraisal of electroconversion in treatment of cardiac dysrhythmias. Br Heart J 1968; 30:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/7\">",
"      Elhendy A, Gentile F, Khandheria BK, et al. Predictors of unsuccessful electrical cardioversion in atrial fibrillation. Am J Cardiol 2002; 89:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/8\">",
"      Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 2001; 38:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/9\">",
"      Dittrich HC, Erickson JS, Schneiderman T, et al. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/10\">",
"      Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976; 53:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/11\">",
"      Lundstr&ouml;m T, Ryd&eacute;n L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand 1988; 223:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/12\">",
"      Dalzell GW, Anderson J, Adgey AA. Factors determining success and energy requirements for cardioversion of atrial fibrillation. Q J Med 1990; 76:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/13\">",
"      Pritchett EL. Management of atrial fibrillation. N Engl J Med 1992; 326:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/14\">",
"      Naccarelli GV. Antiadrenergic therapy in the control of atrial fibrillation. J Cardiovasc Pharmacol Ther 2005; 10 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/15\">",
"      Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/16\">",
"      Dell'Orfano JT, Patel H, Wolbrette DL, et al. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol 1999; 83:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/17\">",
"      Danias PG, Caulfield TA, Weigner MJ, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 31:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/18\">",
"      Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/19\">",
"      Schwartzman D, Musley SK, Swerdlow C, et al. Early recurrence of atrial fibrillation after ambulatory shock conversion. J Am Coll Cardiol 2002; 40:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/20\">",
"      Gurevitz OT, Ammash NM, Malouf JF, et al. Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. Am Heart J 2005; 149:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/21\">",
"      Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/22\">",
"      De Simone A, Stabile G, Vitale DF, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999; 34:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/23\">",
"      Mann DL, Maisel AS, Atwood JE, et al. Absence of cardioversion-induced ventricular arrhythmias in patients with therapeutic digoxin levels. J Am Coll Cardiol 1985; 5:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/24\">",
"      Alam M, Thorstrand C. Left ventricular function in patients with atrial fibrillation before and after cardioversion. Am J Cardiol 1992; 69:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/25\">",
"      Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for \"atrial stunning\" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/26\">",
"      Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/27\">",
"      Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/28\">",
"      Bertaglia E, D'Este D, Zerbo F, et al. Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm; a randomized study. Eur Heart J 2002; 23:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/29\">",
"      Van Gelder IC, Crijns HJ, Tieleman RG, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/30\">",
"      Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992; 70:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/31\">",
"      Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the \"pill-in-the-pocket\" approach. N Engl J Med 2004; 351:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/32\">",
"      Alp NJ, Bell JA, Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart 2000; 84:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/33\">",
"      Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997; 79:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/34\">",
"      Conti A, Del Taglia B, Mariannini Y, et al. Management of patients with acute atrial fibrillation in the ED. Am J Emerg Med 2010; 28:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/35\">",
"      Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/36\">",
"      Botto GL, Bonini W, Broffoni T, et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? Pacing Clin Electrophysiol 1996; 19:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/37\">",
"      Bianconi L, Mennuni M, Lukic V, et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol 1996; 28:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/38\">",
"      Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996; 28:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/39\">",
"      Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/40\">",
"      Abi-Mansour P, Carberry PA, McCowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J 1998; 136:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/41\">",
"      Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/42\">",
"      Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 1997; 96:4298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/43\">",
"      Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/44\">",
"      Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010; 106:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/45\">",
"      Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/46\">",
"      Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation 2000; 102:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/47\">",
"      Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385.",
"     </a>",
"    </li>",
"    <li>",
"     Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study (Abstr). Circulation 1998; 98(17 Suppl): 1633.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/49\">",
"      Banchs JE, Wolbrette DL, Samii SM, et al. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. J Interv Card Electrophysiol 2008; 23:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/50\">",
"      Vietti-Ramus G, Veglio F, Marchisio U, et al. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. Int J Cardiol 1992; 35:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/51\">",
"      Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990; 65:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/52\">",
"      Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1996; 27:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/53\">",
"      Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/54\">",
"      Mart&iacute;nez-Marcos FJ, Garc&iacute;a-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/55\">",
"      Chevalier P, Durand-Dubief A, Burri H, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/56\">",
"      Peuhkurinen K, Niemel&auml; M, Ylitalo A, et al. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol 2000; 85:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/57\">",
"      Blanc JJ, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999; 84:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/58\">",
"      Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/59\">",
"      Tieleman RG, Gosselink AT, Crijns HJ, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/60\">",
"      Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/61\">",
"      Vardas PE, Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000; 117:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/62\">",
"      Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs 2008; 17:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/63\">",
"      Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/64\">",
"      Ferreira E, Sunderji R, Gin K. Is oral sotalol effective in converting atrial fibrillation to sinus rhythm? Pharmacotherapy 1997; 17:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/65\">",
"      Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/66\">",
"      Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997; 18:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/67\">",
"      Roberts SA, Diaz C, Nolan PE, et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 1993; 72:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/68\">",
"      Anderson S, Blanski L, Byrd RC, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group. Am Heart J 1986; 111:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/69\">",
"      Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med 1981; 94:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/70\">",
"      Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/71\">",
"      Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/57/22426/abstract/72\">",
"      Saksena S, Prakash A, Hill M, et al. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 1996; 28:687.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1025 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22426=[""].join("\n");
var outline_f21_57_22426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H872637764\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8701623\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H952132725\">",
"      CANDIDATES FOR CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H412568\">",
"      Unstable patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H412561\">",
"      Stable patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H166080599\">",
"      Reasons to not cardiovert",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102941455\">",
"      DECISIONS BEFORE CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701631\">",
"      Ventricular rate control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701646\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H413218\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H413338\">",
"      DC VERSUS PHARMACOLOGIC CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414573\">",
"      Choice of cardioversion method",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8701654\">",
"      DC CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701669\">",
"      Pretreatment with antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701684\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701706\">",
"      Hemodynamic changes after reversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701722\">",
"      Recurrence of AF after cardioversion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H952133140\">",
"      - Maintenance antiarrhythmic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8701755\">",
"      ANTIARRHYTHMIC DRUGS USED IN CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701769\">",
"      Flecainide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701777\">",
"      Propafenone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701784\">",
"      Ibutilide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701791\">",
"      Dofetilide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701799\">",
"      Amiodarone (intravenous)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701807\">",
"      Amiodarone (oral)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701815\">",
"      Vernakalant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701822\">",
"      Less effective drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8701836\">",
"      - Sotalol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8701843\">",
"      - Dronedarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8701851\">",
"      Ineffective drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H872637949\">",
"      SICK SINUS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H952133456\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H872637764\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1025\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1025|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/37/35423\" title=\"algorithm 1\">",
"      ESC cardioversion strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1025|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/11/19645\" title=\"table 2\">",
"      Drugs and doses for pharmacological conversion of AF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43528?source=related_link\">",
"      Mechanisms of thrombogenesis in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=related_link\">",
"      Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=related_link\">",
"      Therapeutic use of ibutilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_57_22427="Complic salvage surg prostat CA";
var content_f21_57_22427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Early and late complications in three contemporary series of salvage prostatectomy after definitive RT for clinically localized prostate cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year of treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Early perioperative complications, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Late rectal injury, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Late urinary continence, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Late anastomotic stricture, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ward, J; 2005",
"       </td>",
"       <td>",
"        1990-2000",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stephenson, A; 2004",
"       </td>",
"       <td>",
"        1993-2003",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gheiler, E; 1998",
"       </td>",
"       <td>",
"        1992-97",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22427=[""].join("\n");
var outline_f21_57_22427=null;
var title_f21_57_22428="Adolescent contraception tips";
var content_f21_57_22428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for increasing contraceptive adherence among adolescent females*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Contraceptive method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential barriers to adherence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Strategies to increase adherence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Oral contraceptive pills",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Failure to refill prescription",
"        </p>",
"        <p>",
"         Forgetting to take pill",
"        </p>",
"        <p>",
"         Using pills sporadically",
"        </p>",
"        <p>",
"         Not using a back-up method when necessary",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Tell (and ask the adolescent to repeat back) three things:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - When to start the pill",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Take the pill every day at the same time (eg, when brushing teeth)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Call the clinic/office if there are any questions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desire to avoid monthly periods",
"       </td>",
"       <td>",
"        Extended-cycle or continuous pill use",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Depot medroxyprogesterone acetate",
"       </td>",
"       <td>",
"        Failure to make/keep appointment for next shot",
"       </td>",
"       <td>",
"        Schedule the appointment for the next shot when the adolescent is in the clinic/office and ask her to set the alarm on her cell phone as a reminder",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Transdermal patch",
"       </td>",
"       <td>",
"        Requires weekly change",
"       </td>",
"       <td>",
"        <p>",
"         Use a wall, computer, or cell phone calendar",
"        </p>",
"        <p>",
"         Use a cell phone alarm",
"        </p>",
"        <p>",
"         Place a sticker designating the change day on the bathroom mirror",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vaginal ring",
"       </td>",
"       <td>",
"        Requires change every three weeks",
"       </td>",
"       <td>",
"        <p>",
"         Use a wall, computer, or cell phone calendar",
"        </p>",
"        <p>",
"         Use a cell phone alarm",
"        </p>",
"        <p>",
"         Place a sticker designating the change day on the bathroom mirror",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Condoms",
"       </td>",
"       <td>",
"        Must be available at time of sexual activity",
"       </td>",
"       <td>",
"        <p>",
"         Provide condoms to the adolescent before she leaves the clinic/office",
"        </p>",
"        <p>",
"         Suggest that the adolescent carry condoms in her purse",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Provide the adolescent with a list of the following information: the clinic/office name, a contact person, the clinic/office phone number, and instructions about what to do if they miss a dose.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22428=[""].join("\n");
var outline_f21_57_22428=null;
var title_f21_57_22429="COP vs IPF duration";
var content_f21_57_22429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duration of COP and IPF prior to diagnosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A comparison of the duration of illness prior to diagnosis in patients with COP and IPF. Seventy-two percent of patients with COP (n = 92) had the diagnosis established within three months of the onset of symptoms versus only 24 percent of those (n = 25) with IPF.",
"    <div class=\"footnotes\">",
"     COP: cryptogenic organizing pneumonia, also known as bronchiolitis obliterans organizing pneumonia (BOOP); IPF: idiopathic pulmonary fibrosis.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: King TE Jr, Mortenson RL, Immunol Allergy Clin North Am 1992; 12:461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22429=[""].join("\n");
var outline_f21_57_22429=null;
var title_f21_57_22430="Gastric bezoar abdominal x-ray";
var content_f21_57_22430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric bezoar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 267px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAELANgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5kVGYKeSw7dc//qqwlvggjJJBPrk+tadvZHAVh8vcZxWnDZY+4B15PegDDhs3ZhwSPbvVuPTjkggk9z/9at+3sMgHA/EfnV4W6ohVR83PzYyaAMGGxRdzNjII4z1ouIP3mQA3vjpW21vvyMfLn/JpfsuJeBxQBjxWjlQp5yOB6/hV+zsmQrnGM9hV4W67lwMY9KsRRHAAycdqYEthHtJxXd+DSgn3jhwcAHv9K5KxgYsCRXbeDbPN7GWJwDv/ACpiO3S7IOGU9PXmp/ORk+YHPWpZIkZA4xkiokxg7uo5AoAu20wMQAzVLXpMadO/oh61esYx5eTjOaxvFbAadMAflIxQB5FqlyC7gHOfess3sifdYAVd1W3YMzAVkNETnOcj9KQy0+oE7VcEgc1C9x5hO0giq7xbhnBz0psdttJwcZPI9aAG3W1j1IbBPFc5e7143AjOOK6k2qyMSeaqy6TE4+6RnnNAHHXT4yTg9fpWbOT8qnIOOCDknvzXb3GhQSKQV56+lYd/ojJnyyTnnHpSA5skgMewJNKOCxBxgdRU8tpIm7gjBIPv+NQEY+/wPfp9KAAEqAX+ufX3oZsj5htJHFRk5/H8aXqWJ649aAJeTzuGSD+OPSiolIAPIxjByMiigD0G2tAoyRyPXir0UKjGATToYCAMnPOauRQ88DmmBHHG2OnFSrBgd/xq3FDkrVlICT060AZ4tsnJ6UrQZIwGzW1DZEgbu9W0s1QDgZHegVzAWxbJyCBVuKJITknbnpnqa0bpM5EeCf0FVDbkkM2SaAHW0n74COPBB6tXong6AfZ5JdnzEYHNefwQkSDA5969E8PyNFEsXHIHFMDpGGFC+gqPyjngZB4pEZ8EdvU1PGzngAcmgCe3GyMA1h+Jkzps28HArYLuDgLisXxJIf7KuFOScD+YoA80vZIzlWUgevWqT6fHIMqfmPcHIq3Ou9iMd/zp9tAyYKnFAGRJp8idVJHrSLYnOSO9ddbiOQ7WXB6YPQ/SmXlnGufLGCT0osByzWu1+AcU4Ww2lT9QcVq3MYjIyMk+lMARk6/N6UgMeS2wMH0qlcWoI6VvsiP259Kglg64H50Acfeaaj5JBIz0ArHvNEBViqng5FdtPDtBBHFVJIcqRQM83vNLkiJ2BjxnH9ay5YmQMJFbj0716RqFmGyQOT1rnNQ09csMYyO3r/nvSA5gbjgDJPpn+dFWbm1aB+RlTwB1ooA9YhiORxV2KLsBTreEtjHT1rVt7YLyRzTEQW9sSOmB61pQ2wWpIkAAyMYqQNj6CmA8qo7DIpjo0oH90GnAFmHFTqny4HAoAptbntR9m5AxWlswOnarVrZ78Mw+X9TQBjwWjAgkHGTXd+HrMJEsjnOcflWb9jUlVC+mAK6nT4RHAFAGAaAJnVQSMU1Dj0qRxuDe9QAkMR3z+dAFiPBNYXiiPfYylOpIB5rbj+TGTzVTUYw8DBgCp6igDzRrFuWIOM8igRsDz6100UEcjEKe/Q9aiutLUgugxz0oA5188ndz3z3pBdFyI2OT0BFGqRtbOFBIJ7Y5pLGL93ls5bk0AK9qrcNn2PrVabTeAyEqw9K1kfYoDKpGMc84pWC7cZzkZoA5eVJ4Sdy7veoYbgOxD8e9dJNCHBBAyfase+skyWXr6gUAVpIwwz1BqhPAFyRj6VYUywsQQdualmAYZz1pAYUqEnpVG4tVbJFbs6AHjvWfcJ6HBoGcnqum4Q7R8vOcUVt3So6HdwRnmikB2NvgAdKuLKOM4rOSTn5eSasRnJ5NMRfSUsQOOKsRDcD65qpCQCMVeh6fzpgTRKOeKtwx5bAXJ9qjgQyNgce9a9vGkYzgfjQA23tFJBc4HYY4q/I8VvhRy3Yen1qpLcY+WPrjk+n0qNPmY5HNAFxJWllT5yq5B2qMVtQ3LqMLyDWHbrhgOM/yrbsIwQpZhnGaALQkfkfzqRXJGTgkVG7IDgd6RZeQB1oAcZG3crVK5kdnKjJ54AHWrqMrNyBnFQahEhzgHcOtAGHNFiVjjgngipoZi3ySdOganOvynOcE0wxgKCMcnnPSgCvq+mR3IRgoyD2rP+xmNDla2YZCjAclfQ/0qSUJKgzyDzQBzkkAHRcVTbcvzAY7VvXNqyKCFGMcisS9yrHA69qAKrT7G5B/Piq082Q2AOeadM3ByMHNZ87HJ5oAhnYLknB5qrctgAofellkyCGqu0gHB5FIAkYPGCB/9aqEw59KvRsGVgBz61QucgkUDMu/Ubc56Zx25oovmBXAYEdaKAOhhfpzWhA9Y8LdKvwNQBrQt83atS1TdgngGsuzTJBbj2rWicIuB+eKYjSh2oPSny3G4YVuO/vWYbjfkD6Gno+OO3egC8uM81YVwgJzj3zVKMsxGKhvZxEhBYnA6UAW21HZny8bgK29MvR9ntdw++A2c/WvOnvGLMEyWI5PpWhaa7cQwJGApVRjDenpQB3r3wQAsflPBPpU8NwHXcjKw7EVxseqSSIrJGu1uxre0N2Jz5XB6nd/SgDftjltxGadcj7xwcEf0qv5zZIVQAKoT6lIWZSCAOgNAFjarIVBBGahliYKduSP5Vni5YTEqcZNXobsFR5in6igBqcYx19PWlbC4ZeCffg1OypIuRznvVO4DL1HHrQA6R1cHnIxk57Vh38Qck/kauzPtB25zWfLPk7SMd6AMe7AUkc1lXJwDW3eqCCRWBejZ1PHrQBQunBYkDHsKoyyY/Cp5m5/GqUx46c0hk0MvP1pbsb1PrjtVFHIf5fXmrDzBqAMi9cg4Iw3P40UmqYZXIPIHI9aKQG3Cx4rTtBk5PSse1OQCeK045go60wNqKUKMcetTfaQwIA/GsVbjJxnirUMnA5oEa8MnH+NXICoOSecVjxyHoKsJJkA5OaYGw92qRsV546iuc1C6eZyueB6VfkkJjI7EVkrH5j59DQBDAxLcLkEYyOK6DStGuLtd0aEgYyewqlbQLuAwAPeu38N3UUVrHGpwPM2/XIoAdZ6GkCgOQwHetq3jihRRGijHpWXqepmFmWPGG6HGais9WkMmJkBHUYFAG/hSTjrUFzYKwyAMnnBPNQW07zsMDaAeee1W5ZG81T2xk0Acz/F8vIyce+KsK5wM1QvLoCZtuFOfmA/pVQXUrYUMeeABQBvxzFQSDj2p7XCupB4OOlY0UhjT5nJzUhmzyWxQA+8JUkqDj0rIuZdxyepq/PcgjBPPv3rLuyMbs85oAp3M/YtWfcOJE56ipLh8jnis6aQrnPSgClcja1UZjkVdkcSdT05qlPwfrSGUpXMWCOue5qusxQMFY4PPIpbqTaecVSdsIQAMnuRQwG3c+8ZB6g45oqhdyYbPr3B6UUgOvgbagxxU4cnntWVDNuxzkduetX42zimBfgPer0Bz0rMhbmrsDY9vWgDSjYg1MrAc5qjG3PWpi/Bx9KBFuKTJzz6VKqRgl26VVR8gdPaorufaFXPQUwLHnAyjDYA6CtrRtSigUpINy5BBIztI71y5jmgeI3EMsQlTehdSu9SSAwz1HB59qs25LOQM+9AHbrcWzJ85DKe2Ov41PAtk0owXPGPvViadCfs4Vs5znmti3hKqHyQAQelAGla3sRJVPlXr7D1zUMmrRvuVN2zufX6Co44tplj4+ZSAcVnyWrqAChGDjIoAScRzyblTc56DbyarMPKchl2H0IxXSfD+4hs/GOnSXkscMSCTMkjhVGY2HJPHtXRX02j6hqemHVLm3lnjspU8t7gTxpKGBQvL0bI3Hk4BAoA83d+G2jj3pDLyD1r0C0g0dtWvJfJ0QWywIxt3uo/3kuCMI27ao6E9cfjVKBdD/sjNwNMUeXcfasSDzlmyfLEQzkr0xjI65oA4W7mjLExoVHoTms2eU44r0+6tvD3/CMqHl0qS5RbVo5Y3RHYl1EgK53cLnO73OBiuF8c3FlJr13BplvZw2kEjpG9sSwlXPDEliD+GBRcDmbh6yrqUBCavXJOeKydQUvAyqcEikBj2l+rXUkRbnJIyf0q+5DDn0ri7qRorrdzlWwSQa6O1vA4Vc8EcGkMgvOHYY571n3TqFKtjbjJq9qEnOeMDjrWNcPtBIPOOvTNAFS5kJJK7SwGee/NFVbh8jsCTznriigDq7eQgKQeOn1FacEhP1JrFt2wPQjr6mtG2Y7gMk9+aANaI56dquQtWdA5xz/KrSSBRycfjTA0A+P89Kc8+wday0vA0mFI+lRTXPJy1AGvbXmJwHPytxk19JeB/BvhOz0W215UF9mHzvtN2MiMDlvk6DGD6kY61836LbWtpYjXNdVjZgkWdr0a9kHbjkRg/eb/AICOem3F4t1e9tL2Nr+WOG+j8uaFPlj2jgKF6KAABx246UAU/GfiKXxJ4pvtTbcElfEKH+CMcKPyH5k1d0CWCO2Ekyb5GOOpAA/x965qWExnp0rR0iQeT5TsVJfcOM446UAdtcOtvcbQQVPIoXVnXKkgIOigc1jTXZuDl8qw6E9Kmgs5plDIu7jsRTEdDZ6gJ23HG4nnAx/+qtW7kWJEG1CGU7ty5rnNOhMUoMjAEdQOa3ZZI3gV7gsFHI5+9QBhahFsvT5eAhUYHpkZqrJwnI+ap76USTiRcZYYI7VWZsqQaAEHCcEf4VXlbBzTzIMYFQStgjPNAEM7Y9M1nztwcVanb8KoTN8vPWgCncScEZ6VQnc7T6VZuH646e9UJ3pDMfVbBblSYwBKDyPWsgNJbybW+UHOBiumb5j3qhqEaSfejB7ZxSAyXmLqCT82OmetZ1y5BJx35OeK0ZkWPG0georJvMng8MT1xQBTchmBGdoyc/1ookIHIx8wIPPQcUUAdHC+FHzY5GCKuwSYIGfwrMiYlcZ6f5FTCUJk7sZ6AUAbsMwGSx7c1WutSXcY4iQemcdTWHdaiVQop68etVLW4IkDHpnkk0AdXZMwBZ8j0Fb+jaRbRWy654g3/wBmKxENuG2vfOP4F9EH8T9ugycVn+FI9Ou/Pv8AVrgJZ2oDNbo4E1yxPyonp05bHyj1OAZdX1qfXNQWW7CJFGoigt4xiOCMfdRB2A/M5JOSSaAJr2/udc1N726VASAscaDEcKAfKiL/AAqOwqwmIFAJptoVC8UlywYnHAxTAuQyrIpVuR60SQSRDdESRnqDWbFNs6A4rovD6i9mVDkjr7D60CI7e7mkteQQ6nGfWrdhd3MB5OO4Nb0+jwLH8i7G78cZqhdW72w2bUZhjtmmBdgkm84yn7p5pl/PctP+8z5YAxx0pdNvI5AYtwLLx7Gt37Gk1vuk2oBxuJ4oA5tXLfT2qRmPAx+lS6nZ/Y5BjGxjhWByDVMtyDQAkjDn61E7jqetOkb5snGDVOWTk4PANADZ5B09Kzbh8L61LNJx1rPuJRikBXuJMEniqcpJxxUsrbiTzSbBwTQMhOdoBHPHSqN0wyfXk1clYK5A6Z59qoXfOSW4/WgDIuWG0kj8c1lXCgs44OffrWrdsAQR3P1rLkG3cOAB0/8ArUgKTE7ARnJz7E0Usm3aeMH/ADzRQBrRsdvGcYwABVfULgl9qEgjPtUbTiJRtyzHpVVnLtj7xI5wetAAz5wCflx1HP8AntT7cbiMcsfXnv8A5/Kkhg3sRySc5rYtrKO2VXujz12jGTz6UAXNMPlxkuwweueK07Vd5V2JVQe9ZJvgzBFijVQegHNW7eUyHIJHP04oA6CGQknHSrG3eKpW2AoBGMVchfHPemA9kGwAngVf0QlVVRwmTx6mqRPmIRnkVPa3rWsWIsZ5Pbk0AdJc6o6geW5JXAIPcAVJDd+cm5+rfezXNW86SJuLsrg4IrptAmiRSSFd+2QCBTEV47KVJw8I3D6dPrXWQTieyMQ3eYuDjvx1rPubuNZCRhR14FPlvbeK3DKx83pu4FADb2Um0wRhfMGAfoazGweTjrTLy8Mow0jPz3qpK0rD5WC/QUAS3ThF+Y9+9Y1zdDzCF55q29qW+/ISfeoJLNQeWpAZ8krufSoDGznqTWq0aIOFH41BJjHy9aBns+lfDzw94+8J2ur6WRpWqMvl3AgXMPmr97Mf8OeCNpGAehrx3xx4fu/CeuSaXqEkEsyqH3QvuBU9M9wfY/1roPBPxA1LwZaalBYRRTfawCnm5xE4434HXjt9PTBq60g8aRXGsWWRryL5l/aZz56gczRfTHzJ26jjgAHBT4OcHnNUbhy2c5HFW7hvmOOufyrMumXcSMAUAZ11kE4z+NZk/O4YOM9DWhOcFT19qzZCG7cdc9MmkBWk4UDqCMZ7UUSg4+gzRQA8BiUILevJqVIowVDtyPbpVNScEDIHpnirVuu453YAz+AoA0bZY4E35BA5A9KhmuC7ktglh3/p60+JwjMsg+VgMk4pjRZOEww9uCKACFxnLEHnt/8AWre0naJ8NySODnpWVBbSddpUjp6Vs6cp8xRjJHYfWgDWX5WCj86sbiFojT5gT+NWSqKpJ644pgU5JPLj5OB3OabbHzhjt0J602RfNBGSp7Edq19E09IokYsJGBJ2nigAtrBm2gZyTngV1+l2P2e22hGLY5OKS3Agt0nVtrjJCqOKmg1eZmPznjqPWmIS4ildjiFgMDPy5qH7FIyMsiMo46irJvpzI7eY5L9ea3LG5/0Z2LsZAucN3P0+lAHHXMJj6jpSZ6YHWt/WZlu4pQygPwQRWDtZUA9KAGOOMelV5STxVkn5R71A+CTQwKTE9xUMudtWZQOaqSkBST60gKk3fFMt7q4sLuK6s5pILmFg8ciHDKw6EGnyMGBxmqsxz3xxQM39Utrbxbaz6no0KQ63ApkvtPjXAmUdZ4R+rIOnUcZA89ucMGx0HeteG6uLC/ivLGeSC5hkDxyRnBRh0Oa2tctbTxXp1zrGmJDaaxbI0uo6euFSVR96eEfqyDp1HGQqA86uMAnaSRnGOlUpRgnB59R/Wrs4w2eeOtVJAyk4PynjHtQBSkB+XBx2ODRTp8YOTnIPUYxRQBGOUUds46e46VajfD/NjjnqMDj/AOt1qpn5QN3Bx1OKkU4fOcY6nHTHv+VAFuVflV+Ao6e5prSFGxk7qdg7Vy43dCehqFwCu3PUEgen40AadlOzpjJzjPJrXsZyACMjPXjnrXOWwId1XnnJFaNrI5Y5bjuc0AdlavvXk5NPd6xbK+SOQfNuHQ1qyKJAHQ5SmA5QM8cVsaY8ZKCSTYu7DHaTgVjRj5QOa2dPtg2xSWGTzQB0F2REixx5ZFHB9fek0qAS3Sl1JUc9cZFT+VD5QEs54H8I4qW1lsYAR50n3c8gD8aYi8beMKWVApxyKsaaiqC8hY85AHFLFPYeUD5rksOmRTUuLfgRFzz1NAFDUp4WMrRwPGP7obPesd5BjKnNdBqLRsg2g8VzDKY5GRuMc0APdsj0qF2OKkYnAqGTdg0AVZm49aqu2eOoqeVD+Jqq6n0pDIJTVWYjngGrTxv/AHTmqk8bHI28UAZ1w+WbBxjis+4PDY7+hq7MrqTlSOfw/wDrVm3ORnevboeKQGdM+WPOF9Tx2/8A1VVZiyv0wOPp61JM+5jk8Z6j6+9Vmf5Tng+nTmgCKQliuQe5OB1/woprnOQcfqO1FACrFv8AmyTyO1WYkBGVHOOo/wAKekJCY2g9sHtmr9vEU6rnjg80AVmhYHaN3Tr/AI0eUcquMCtqOAuvGd2aEtGMiKU6HmgDPjtAsZkxuGcDioXRtxBzgkDPrXVC0VonXB56YrNNkyPjk4NAFG1jYtwDjPUDpXW6SjNHnnAHOazbK0JnUDJHriustoRDbhQOMZpgVYY1DhmUMR2rpdDEM8hjK7ZMZBB71z8QLy4Gcmun0a3igeNjKGZuCR/CPSgRm6o1wr7RkcDtwKzolmEu/BY/XOa67U4PKYxCPIHdjUVhCwchY1UdWbApgU7GzupoVYxnnjOK3tM0u55ectsXsetaTb1+RcDHGfap4I12bWkwc9ORQBmapFGvlrGvylc7j1rFubcBh0PHNdXdsscbRsgcnkbh0965icMHJPPpQBTkiAGCuB2qi2SxB+nNarqW6+lQR2hdzwfU0AZxgZyKQ2yoMgZPvW79mAUAD9Kr3MBAzjpmgDn5U+uaozR8nituWP8ACs+4jwTmkBiTpk/d71kXkYw2crgHuRiuhlT5mrOuogwIx75/CgZyNwiszbQMjngYNZ8yFWY9AMdPT61u3duA+cDPXFZssJ+ZiDnH+TSAymGNvOMZx/n6UVNPG0ZwMgHn04/yf1ooA04twAB6E44H0q9bPlhvYHPU+hqukJZRgHAx92rcVswYfLwepFAGtbADBYYJPftWlEnAXHH0qtbW+VAYfWtKHC8daYDY4/zqVoQw2sM9qu2kKyMCKviyAOWoAxYLdYnAxz2q5KWEa56HqavizV/qOajuB5cJHOBxxQIzbeRfO2gjmt+0LpHvwSV6eh+tYVoEEu8pls8V3Og7MKJoYpE29xTAk+1XDxorsD6kgGpUmkKEkgj2FaZsrby8jIGcZBqAWsXzAbgM9c5oAqo7sCWYnJ9aUl8DaT+FXltYwAFOQewq9b28aLuYAigDOVJfJUSgnjO49h6Vh3DKJnVnA2nFdPqlwQQuBtwCOwrHlKO2SF3euKAKotWJHA5HFaEFmFiGVGTyam09C8igAbVFXp4WXn+Fv0oAyjbjjAx71VubbC/UVupCMop6H0qLULfahxkjFAHGXMHJOO9ZdzF6Dmuiuo+SKy7iPrxQBzcyYbpVKaPg/pWxcxYY1nzL1pDOev4uRx9MVlTR4DDn8q6S8jPUfjWTPHtB4OBwPUc0gMKZAFK4wTmircyAjoOf5/8A66KAL1rGMDb0x9MVfh4ZRtGentTIYyVGO+Bz61bhgBY5GR3JoAvW4yg/rUm5V4Y/lUS8jA4UcUFNxGDTA1NPuQsijbxnqa6WaNfs6yDJzXK6fAzyKO+a7GBdtiVlGBxg00IpxqQuR0JxxUNzDuLL61dt5ISHUsePmpr7GHykEZ60AZlrZgSDcCcdTXU6dKFiVQgz3asqHIbcRkVr2TwoASO3HPAoA0mnIULt5pN0jHgYp0MkUjxhCN3TOeKvlbdQdpOexoAoIk3YnP5Vah8wfIx/AVYhlQhY/uqOetSOiovydSCAQKAMu8MgBjkw6DnpnB9qrmLkEfnVycvH8u4E+1Q4yPr2oAlsQI8nPtWm/wA8J4zjB+lUrePODkZPAFaKpiFh096AIrdMrk0l6m6DgfhVi2ACgY96bOMRse2KAOQvoyGIHT1rKlTg5rfvV3SHABB5+prIu1HJHWgDBuosseOayLqMrnAroJgM8flWfcRq7HPWkBgumQQRmqNxbA9QDxW5NCB61UmT2oGc1d25G7d9OR/WitO9i+Rm7daKLASpBhejDPXmpUVgec+9W9mOcUGMelAESrgcZFWIYgQecetRgHP9asQx7iMdfagDb0iKNZNzfdFat1doY2AGTjGPSsdEKoP5U+ElQd3f1oERwSZnJJ+9kVoW0RywPYZ/WqiQ5bKr1NJcXzQ3EaHoBjI70Aa0sqQRYXDSHkE9F/8Ar1Qa9YH5myT+lRi6A+ZsYPX1rFv7gmb92ABTA331l7dRtKlyMcccVZtdamkUjOD61ykG2TO/kg9c1eimWKPEeAc/WkB1dtqrgjc3J6ZrQN1cTop3nufSuP02VjOGdM89DXVoyLa7OhYZApgQrPOZSGkb0rQs7qRG2TgOh4yQMr9KzV3bs5x6VOs5xhsH6jkUAbwk8t42TBBJ56Zq95qtGFBxn1rkGu2DKFPyA85rYgmeMDfu3HB2+3tQBuR8HGegplyDs4HPWmxv8wye1OuGVkPUnt70Ac/doXc+5Pasi5jIHzda6O4QFcgHpz9axrxCFPTPrQBz0yks3pVZ4+uBWhtJky306VG6ZzjigDJmiyTwKoTR47dK3ZI+46VRuUwvNIDn7yMeU3UCiprwcEEUUDLgTtTfL6gjg1ZRQQOKD2oArRw/N8uSemBWpZWwVgZPvZqGIAHgVcjJPJ65xQIuSxg7cZCnoKj8osyAAdelW7TlWz2qWIAyLx3pgQ3EL29uX2YXvIeFX8a5m7lSWUCL5lX+L1Jq34vmke/t4GdjCkQYJnjJzzj1rKj+9SAn8zavJJ9MUyV0ZAfut2z3ocDn8KhukXyl470DHwRyMzED5amETBjyT3NXNCRWD5GeM1sqq+WBjjrQBSswsIVnyMdPrWtFeoyYfcD6kVnzqC8WR160+ZR9ki4HemI04J8ycAkY60+aTHSs6wdsdenSpskuQaAJM5U57nmrdnql1aKFR98X/PKTlT/UfhVEk4x70xicLz3oA7LTr+DUEKxIY7mMZMROePVT3/GtNlwpIB6A1wGlSPHqlq0bFT5ijI9Cea9GnAwaAMmZQwO5lHGMnPWse6XqxAyOB3rbueGWsK+JBwOgzigDNkVck8ZPWqkozjgippCfm+tQnqfpmgCKTG09ayr51EZ7VqXPCcd65/VGOAM8GgDH1CYlSBwPWiobz7hoqRn/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This abdominal x-ray shows a distended stomach with an air-fluid level outlining a large gastric bezoar (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22430=[""].join("\n");
var outline_f21_57_22430=null;
var title_f21_57_22431="Chronic OM with effusion";
var content_f21_57_22431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Otitis media with effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tympanic membrane in chronic otitis media with effusion. The membrane is not erythematous but fluid level can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_57_22431=[""].join("\n");
var outline_f21_57_22431=null;
   